US7897583B2

US7897583B2 - Compositions and their uses directed to PTPRU

Info

Publication number: US7897583B2
Application number: US11/915,309
Authority: US
Inventors: Robert McKay; Ravi Jain; Kenneth W. Dobie; Sanjay K. Pandey; Sanjay Bhanot
Original assignee: Isis Pharmaceuticals Inc
Current assignee: Ionis Pharmaceuticals Inc
Priority date: 2005-05-24
Filing date: 2006-05-24
Publication date: 2011-03-01
Also published as: WO2006127976A3; EP1924294A2; US20110112171A1; US20080280845A1; WO2006127976A2; EP1924294A4; US8202981B2

Abstract

Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.

Description

RELATED APPLICATIONS

This application is a U.S. National Phase under 35 U.S.C. §371 of PCT/US2006/020388, filed May 24, 2006, designating the United States and published in English on Nov. 30, 2006 as WO2006/127976, which claims the benefit of priority of U.S. Provisional Patent Application No. 60/684,398, filed May 24, 2005. The content of these applications is incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal.

BACKGROUND OF THE INVENTION

Phosphorylation and dephosphorylation are ubiquitous processes within cells that greatly influence cellular phenotypes. The extent and duration of phosphorylation is regulated by the opposing action of phosphatases, which remove the phosphate moieties. Consequently, considerable attention has been devoted to the characterization of tyrosine kinases and tyrosine phosphatases and their associations with disease states (Zhang, Crit. Rev. Biochem. Mol. Biol., 1998, 33, 1-52).

Protein tyrosine phosphatases are signaling molecules that regulate a variety of cellular processes, including cell growth and differentiation, cell cycle progression and growth factor signaling. A number of protein tyrosine phosphatases have been implicated as negative regulators of insulin signaling (Zhang, Crit. Rev. Biochem. Mol. Biol., 1998, 33, 1-52). Characterization of the protein tyrosine phosphatase PTPRU revealed it to be a member of the type II receptor protein tyrosine phosphatase (rPTP) subfamily, which includes PTP.mu. and PTP.kappa. PTPRU contains many of the domains characteristic of this subfamily, including a transmembrane domain and two tandem intracellular protein tyrosine phophatase domains. In addition, the presence of the extracellular immunoglobulin (Ig) domain and four tandem fibronectin-type III (FN-III) repeats, which are common to cell-adhesion receptors, suggests that PTPRU can contribute to the mechanisms of cell adhesion and homotypic cell interactions (Avraham et al., Gene, 1997, 204, 5-16; Crossland et al., Biochem. J., 1996, 319 (Pt 1), 249-254; Thomas et al., J. Biol. Chem., 1994, 269, 19953-19962; Wang et al., Biochem. Biophys. Res. Commun., 1997, 231, 77-81; Wang et al., Oncogene, 1996, 12, 2555-2562). PRPRU also contains a MAM domain, which, along with the Ig-like domain, is required for the homophilic interactions displayed by PTP.mu. and PTP.kappa. (Avraham et al., Gene, 1997, 204, 5-16; Crossland et al., Biochem. J., 1996, 319 (Pt 1), 249-254; Wang et al., Biochern. Biophys. Res. Commun., 1997, 231, 77-81; Wang et al., Oncogene, 1996, 12, 2555-2562).

Owing to its simultaneous identification in several different cell types, PTPRU is known by many synonyms, including protein tyrosine phosphatase, receptor type, U, also known as PTP-RU or PTPU2; protein tyrosine phosphatase receptor omicron or PTPRO; protein tyrosine phosphatase pi; protein tyrosine phosphatase J or PTP-J; pancreatic carcinoma phosphatase 2, PCP2 or PCP-2; protein tyrosine phosphatase psi, receptor type, R-PTP-Psi, PTPPsi or pi R-PTP-Psi; glomerular epithelial protein 1 or GLEPP1; and FMI.

The expression of PTPRU is developmentally regulated. During early development expression is mainly in the brain and lung. In adults, PTPRU expression is in the kidney, lung, heart, skeletal muscle, pancreas, liver, prostate, testis, brain, bone marrow, and stem cells (Avraham et al., Gene, 1997, 204, 5-16; Crossland et al., Biochem. J., 1996, 319 (Pt 1), 249-254; Wharram et al., J. Clin. Invest., 2000, 106, 1281-1290; Beltran et al., J. Comp. Neurol., 2003, 456, 384-395; Stepanek et al., J. Cell Biol., 2001, 154, 867-878). PTPRU is additionally involved with megakaryopoiesis, cell adhesion and promotion of the G0/G1 cell cycle arrest in normal naïve quiescent B cells (Taniguchi et al., Blood, 1999, 94, 539-549; Aguiar et al., Blood, 1999, 94, 2403-2413; Yan et al., Biochemistry, 2002, 41, 15854-15860).

A number of tissue-specific forms of PTPRU have been identified. In the kidney, PTPRU is known as GLEPP1 and is highly expressed in podocytes, specialized epithelial cells that form the glomerular capillaries (Thomas et al., J. Biol. Chem., 1994, 269, 19953-19962). In megakaryocytes, PTPRU is called PTPRO, alternative splicing of which yields a lymphoid tissue-specific, truncated form called PTPROt (Aguiar et al., Blood, 1999, 94, 2403-2413). Alternative splicing of PTPRU also yields osteoclastic protein tyrosine phosphatase or PTP-oc (Amoui et al., J. Biol. Chem., 2003, 278, 44273-44280).

In addition to participation in the regulation of several essential functions, PTPRU is implicated in numerous disease conditions. Motiwala et al., have reported a correlation between PTPRU and diet dependent development of pre-neoplastic nodules and hepatocellular carcinoma (Motiwala et al., Oncogene, 2003, 22, 6319-6331). PTPRU expression was found to be altered in several cancerous cell lines (Crossland et al., Biochem. J., 1996, 319 (Pt 1), 249-254; McArdle et al., J. Invest. Dermatol., 2001, 117, 1255-1260; Wang et al., Biochem. Biophys. Res. Commun., 1997, 231, 77-81; Wang et al., Biochem. Biophys. Acta., 1999, 1450, 331-340). Furthermore, PTPRU was found to be hypermethylated in colon cancer (Mori et al., Cancer Res., 2004, 64, 2434-2438).

The diverse tissue distribution and disease associations of PTPRU indicate that it can be an appropriate target for therapeutic intervention in a number of disease conditions.

Currently, there are no known therapeutic agents that effectively inhibit the synthesis and/or function of PTPRU. Consequently, there remains a long felt need for agents capable of effectively inhibiting PTPRU synthesis and/or function.

Generally, the principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and effects the modulation of gene expression activity, or function, such as transcription or translation. The modulation of gene expression can be achieved by, for example, target RNA degradation or occupancy-based inhibition. An example of modulation of target RNA function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound. Another example of modulation of gene expression by target degradation is RNA interference (RNAi) using small interfering RNAs (siRNAs). RNAi is a form of antisense-mediated gene silencing involving the introduction of double stranded (ds)RNA-like oligonucleotides leading to the sequence-specific reduction of targeted endogenous mRNA levels. This sequence-specificity makes antisense compounds extremely attractive as tools for target validation and gene functionalization, as well as therapeutics to selectively modulate the expression of genes involved in diseases.

SUMMARY OF THE INVENTION

Disclosed herein is the discovery PTPRU can be modulated to effect in vivo glucose levels. This newly discovered correlation between PTPRU activity and in vivo glucose levels provides a novel pathway for regulating glucose homeostasis in an animal. In one embodiment, modulators that decrease the activity of PTPRU are provided as compounds that reduce in vivo glucose levels. Preferrably the PTPRU modulators are specific for PTPRU, and more preferably the modulators are antisense compounds that hybridize with a nucleic acid molecule that expresses PTPRU, thereby inhibiting expression of the nucleic acid molecule. In another embodiment, the glucose levels are blood glucose levels, which include, but are not limited to, whole blood, plasma or serum glucose levels. In a further embodiment, the in vivo blood glucose levels are reduced to treat a disease or condition associated therewith. The disease or condition can include, but is not limited to, diabetes, type II diabetes, prediabetes, obesity, metabolic syndrome or a combination thereof.

In a further aspect, PTPRU is modulated to effect the levels of HbA.sub.1c (hereinafter “HbA1c”). HbA1c is a glycosylated form of hemoglobin and is a clinical indicator of excessive blood glucose levels and diabetes. In one embodiment, modulators of PTPRU are provided as compounds that that reduce in vivo blood glucose levels and in turn reduce the levels of HbA1c. Preferably, the PTPRU modulators are specific for PTPRU, and more preferably the modulators are antisense compounds that hybridize with a nucleic acid molecule that expresses PTPRU, thereby inhibiting expression of the nucleic acid molecule.

Disclosed herein are antisense compounds targeted to and hybridizable with a nucleic acid molecule encoding PTPRU and which modulate the expression of PTPRU. In a preferred embodiment the nucleic acid molecule encoding PTPRU has a nucleotide sequence that is substantially similar to one or more of GenBank Accession Nos.: NM_—005704.2, NM_—133177.1, NM_—133178.1 or NT_—004538.15 (SEQ ID NOS: 1-4, respectively), presented in table 1, below and incorporated herein by reference. In a further aspect, the antisense compounds are targeted to and hybridizable with a region of a nucleic acid molecule encoding PTPRU. Still further, the antisense compounds are targeted to and hybridizable with a segment of a nucleic acid molecule encoding PTPRU. Still further the antisense compounds are targeted to and hybridizable with a site of a nucleic acid molecule encoding PTPRU.

Further disclosed herein are active target segments comprising segments of a nucleic acid molecule encoding PTPRU, the active target segments being accessible to antisense hybridization, and so, suitable for antisense modulation. In one embodiment, the active target segments have been discovered herein using empirical data that is presented below, wherein at least two chimeric oligonucleotides are shown to hybridize within the active target segment and reduce expression of the target nucleic acid (hereinafter, “active antisense compound”). The at least two active antisense compounds are preferably separated by about 60 nucleobases on the nucleic acid molecule encoding PTPRU. In another embodiment, antisense compounds are designed to target the active target segments and modulate expression of the nucleic acid molecule encoding PTPRU.

In one aspect there are herein provided antisense compounds comprising sequences 12 to 35 nucleotides in length comprising at least two chemical modifications selected from a modified internucleoside linkage, a modified nucleobase or a modified sugar. Provided herein are chimeric oligonucleotides comprising a deoxynucleotide mid-region flanked on each of the 5′ and 3′ ends by wing regions, each wing region comprising at least one high affinity nucleotide.

In one embodiment there is herein provided chimeric oligonucleotides comprising ten deoxynucleotide mid-regions flanked on each of the 5′ and 3′ ends with wing regions comprising five 2′-O-(2-methoxyethyl) nucleotides and wherein each internucleoside linkage of the chimeric oligonucleotide is a phosphorothioate. In another embodiment there is herein provided chimeric oligonucleotides comprising fourteen deoxynucleotide mid-regions flanked on each of the 5′ and 3′ ends with wing regions comprising three locked nucleic acid nucleotides and wherein each internucleoside linkage of the chimeric oligonucleotide is a phosphorothioate. In a further embodiment there are hererin provided chimeric oligonucleotides comprising fourteen deoxynucleotide mid-regions flanked on each of the 5′ and 3′ ends by wing regions comprising two 2′-O-(2-methoxyethyl) nucleotides and wherein each internucleoside linkage of the chimeric oligonucleotide is a phosphorothioate. In a further embodiment, the antisense compounds may comprise at least one 5-methylcytosine.

Further provided herein are methods of modulating the expression of PTPRU in cells, tissues or animals comprising contacting the cells, tissues or animals with one or more of the antisense compounds. In one embodiment, the antisense compounds are contacted to the cell, tissue or animal and inhibiting the expression of PTPRU therein. The inhibition of PTPRU expression can be measured by analyzing the cells for indicators of a decrease in expression of PTPRU mRNA and/or protein by direct measurement of mRNA and/or protein levels, and/or measuring glucose levels, triglyceride levels, insulin levels, fatty acid levels, cholesterol levels, transaminase levels, electrocardiogram, glucose uptake, gloconeogenesis, insulin sensitivity and body weight

In one embodiment, there are provided methods of lowering plasma glucose or plasma triglycerides using antisense compounds that inhibit PTPRU expression in cells, tissues or animals. In another embodiment, there are provided methods of improving insulin sensitivity using antisense compounds that inhibit PTPRU expression in cells, tissues or animals.

In other embodiments, the there are provided methods of ameliorating or lessening the severity of a condition in an animal comprising contacting said animal with an effective amount of an oligomeric compound that inhibits PTPRU expression in cells, tissues or animals. In an additional embodiment, the ameliorating or lessening of the severity of the condition of an animal is measured by one or more physical indicators of said condition, comprising glucose levels, triglyceride levels, insulin levels, fatty acid levels, cholesterol levels, transaminase levels, electrocardiogram, glucose uptake, gluconeogenesis, insulin sensitivity and body weight. The conditions include, but are not limited to, diabetes, type II diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease.

Also provided is a method of use of the oligomeric compound of the instant invention for the preparation of a medicament for the prevention, amelioration, and/or treatment disease, especially a disease associated with and including at least one indicator comprising glucose levels, triglyceride levels, insulin levels, fatty acid levels, cholesterol levels, transaminase levels, electrocardiogram, glucose uptake, gloconeogenesis, insulin sensitivity and body weight.

DETAILED DESCRIPTION OF THE INVENTION

PTPRU is herein shown to effect in vivo glucose levels in mammals. This novel discovery, therefore, provides PTPRU as a novel target for modulating blood glucose levels. Provided herein are methods of modulating blood glucose levels using a modulator of PTPRU. Preferrably the modulator is selective for PTPRU. Also preferably the modulator is an antisense compound that hybridizes with a nucleic acid molecule that expreses PTPRU, thereby inhibiting the expression of the nucleic acid molecule. In one aspect, the methods of modulating PTPRU are useful for treating a disease or condition associated thererwith, the disease or condition including, but not being limited to, diabetes, type II diabetes, prediabetes, obesity, metabolic syndrome or a combination thereof.

Also provided herein are modulators that decrease the activity of PTPRU and in turn reduce in vivo glucose levels. Preferrably the PTPRU modulators are specific for PTPRU, and more preferably the modulators are antisense compounds that hybridize with a nucleic acid molecule that expresses PTPRU, thereby inhibiting expression of the nucleic acid molecule. In another embodiment, the glucose levels are blood glucose levels, which include, but are not limited to, whole blood, plasma or serum glucose levels. In a further embodiment, the in vivo blood glucose levels are reduced to treat a disease or condition associated therewith. The disease or condition can include, but is not limited to, diabetes, type II diabetes, prediabetes, obesity, metabolic syndrome or a combination thereof.

Moreover, PTPRU has been shown to effect triglyceride levels, insulin levels, fatty acid levels, cholesterol levels, transaminase levels, glucose uptake, gloconeogenesis and insulin sensitivity. Therefore, PTPRU is indicated in diseases and conditions related thereto and including, but not limited to, diabetes, type II diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease. The instant invention provides antisense compounds for the prevention, amelioration, and/or treatment of diseases and conditions relating to PTPRU function. As used herein, the term “prevention” means to delay or forestall onset or development of a condition or disease for a period of time from hours to days, preferably weeks to months. As used herein, the term “amelioration” means a lessening of at least one indicator of the severity of a condition or disease. The severity of indicators may be determined by subjective or objective measures which are known to those skilled in the art. As used herein, “treatment” means to administer a composition of the invention to effect an alteration or improvement of the disease or condition. Prevention, amelioration, and/or treatment may require administration of single dose or of multiple doses at regular intervals to alter the course of the condition or disease.

Disclosed herein are antisense compounds, including antisense oligonucleotides and other antisense compounds for use in modulating the expression of nucleic acid molecules encoding PTPRU. This is accomplished by providing antisense compounds that hybridize with one or more target nucleic acid molecules encoding PTPRU. As used herein, the terms “target nucleic acid” and “nucleic acid molecule encoding PTPRU” have been used for convenience to encompass RNA (including pre-mRNA and mRNA or portions thereof) transcribed from DNA encoding PTPRU, and also cDNA derived from such RNA. In a preferred embodiment, the target nucleic acid is an mRNA encoding PTPRU.

Target Nucleic Acids

“Targeting” an antisense compound to a particular target nucleic acid molecule can be a multistep process. The process usually begins with the identification of a target nucleic acid whose expression is to be modulated. For example, the target nucleic acid can be a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. As disclosed herein, the target nucleic acid encodes PTPRU and has a polynucleotide sequence that is substantially similar to one or more of SEQ ID NOS: 1-4.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as “variants.” More specifically, “pre-mRNA variants” are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence. Variants can result in mRNA variants including, but not limited to, those with alternate splice junctions, or alternate initiation and termination codons. Variants in genomic and mRNA sequences can result in disease. Antisense compounds targeted to such variants are within the scope of the instant invention.

In accordance with the present invention are compositions and methods for modulating the expression of PTPRU. Table 1 lists the GenBank accession numbers of sequences corresponding to nucleic acid molecules encoding PTPRU (nt=nucleotide), the date the version of the sequence was entered in GenBank, and the corresponding SEQ ID NO in the instant application, when assigned, each of which is incorporated herein by reference.

TABLE 1

Gene Targets

			SEQ ID
Species	Genbank #	Genbank Date	NO

Human	NM_005704.2	Mar. 26, 2002	1
Human	NM_133177.1	Mar. 26, 2002	2
Human	NM_133178.1	Mar. 26, 2002	3
Human	nucleotides 751930 to 843018 of	Oct. 7, 2003	4
	NT_004538.15
	(replaced by NT_004610)
Mouse	U55057.1	Nov. 1, 1996	5

Modulation of Target Expression

Modulation of expression of a target nucleic acid can be achieved through alteration of any number of nucleic acid (DNA or RNA) functions. “Modulation” means a perturbation of function, for example, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in expression. As another example, modulation of expression can include perturbing splice site selection of pre-mRNA processing. “Expression” includes all the functions by which a gene's coded information is L 0 converted into structures present and operating in a cell. These structures include the products of transcription and translation. “Modulation of expression” means the perturbation of such functions. The functions of RNA to be modulated can include translocation functions, which include, but are not limited to, translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, and translation of protein from the RNA. RNA processing functions that can be modulated include, but are not limited to, splicing of the RNA to yield one or more RNA species, capping of the RNA, 3′ maturation of the RNA and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. Modulation of expression can result in the increased level of one or more nucleic acid species or the decreased level of one or more nucleic acid species, either temporally or by net steady state level. One result of such interference with target nucleic acid function is modulation of the expression of PTPRU. Thus, in one embodiment modulation of expression can mean increase or decrease in target RNA or protein levels. In another embodiment modulation of expression can mean an increase or decrease of one or more RNA splice products, or a change in the ratio of two or more splice products.

The effect of antisense compounds of the present invention on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. The effect of antisense compounds of the present invention on target nucleic acid expression can be routinely determined using, for example, PCR or Northern blot analysis. Cell lines are derived from both normal tissues and cell types and from cells associated with various disorders (e.g. hyperproliferative disorders). Cell lines derived from multiple tissues and species can be obtained from American Type Culture Collection (ATCC, Manassas, Va.) and other public sources, and are well known to those skilled in the art. Primary cells, or those cells which are isolated from an animal and not subjected to continuous culture, can be prepared according to methods known in the art, or obtained from various commercial suppliers. Additionally, primary cells include those obtained from donor human subjects in a clinical setting (i.e. blood donors, surgical patients). Primary cells prepared by methods known in the art.

Assaying Modulation of Expression

Modulation of PTPRU expression can be assayed in a variety of ways known in the art. PTPRU mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA by methods known in the art. Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993.

Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions. The method of analysis of modulation of RNA levels is not a limitation of the instant invention.

Levels of a protein encoded by PTPRU can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to a protein encoded by PTPRU can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of Monoclonal Antibodies is Taught in, for Example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997.

Active Target Segments

The locations on the target nucleic acid defined by having at least two active antisense compounds targeted thereto are referred to as “active target segments.” An active target segment is defined by one of the at least two active antisense compounds hybridizing at the 5′ end of the active target segment and the other hybridizing at the 3′ end of the active target segment. Additional active antisense compounds may hybridize within this defined active target segment. The compounds are preferably separated by no more than about 60 nucleotides on the target sequence, more preferably no more than about 30 nucleotides on the target sequence, even more preferably the compounds are contiguous, most preferably the compounds are overlapping. There may be substantial variation in activity (e.g., as defined by percent inhibition) of the antisense compounds within an active target segment. Active antisense compounds are those that modulate the expression of their target RNA. In one of the assays provided herein, active antisense compounds inhibit expression of their target RNA at least 10%, preferably 20%. In a preferred embodiment, at least about 50%, preferably about 70% of the oligonucleotides targeted to the active target segment modulate expression of their target RNA at least 40%. In a more preferred embodiment, the level of inhibition required to define an active antisense compound is defined based on the results from the screen used to define the active target segments. One ordinarily skilled in the art will readily understand that values received from any single assay will vary in comparison to other similar assays due to assay-to-assay conditions.

Hybridization

As used herein, “hybridization” means the pairing of complementary strands of antisense compounds to their target sequence. While not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases). For example, the natural base adenine is complementary to the natural nucleobases thymidine and uracil which pair through the formation of hydrogen bonds. The natural base guanine is complementary to the natural base 5-methyl cytosine and the artificial base kiniown as a G-clamp. Hybridization can occur under varying circumstances.

An antisense compound is specifically hybridizable when there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

As used herein, “stringent hybridization conditions” or “stringent conditions” refers to conditions under which an antisense compound will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances, and “stringent conditions” under which antisense compounds hybridize to a target sequence are determined by the nature and composition of the antisense compounds and the assays in which they are being investigated.

Complementarity

“Complementarity,” as used herein, refers to the capacity for precise pairing between two nucleobases on either two oligomeric compound strands or an antisense compound with its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The antisense compound and the further DNA or RNA are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleobases such that stable and specific binding occurs between the antisense compound and a target nucleic acid.

Those in the art understand that for an antisense compound to be active it need not be 100% complementary to the target nucleic acid site wherein it hybridizes. Often, once an antisense compound has been identified as an active antisense compound, the compounds are routeinly modified to include mismatched nucleobases compared to the sequence of the target nucleic acid site. The art teaches methods for introducing mismatches into an antisense compound without substantially altering its activity. Antisense compounds may be able to tolerate up to about 20% mismatches without significant alteration of activity, particularly so when a high affinity modification accompanies the mismatches.

It is understood in the art that the sequence of an oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure). The oligomeric compounds of the present invention comprise at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 92%, or at least 95%, or at least 97%, or at least 98%, or at least 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an oligomeric compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an oligomeric compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an oligomeric compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mal. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489).

Identity

Antisense compounds, or a portion thereof, may have a defined percent identity to a SEQ ID NO, or a compound having a specific compound number. As used herein, a sequence is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, a RNA which contains uracil in place of thymidine in the disclosed sequences of the instant invention would be considered identical as they both pair with adenine. Similarly, a G-clamp modified heterocyclic base would be considered identical to a cytosine or a 5-Me cytosine in the sequences of the instant application as it pairs with a guanine. This identity may be over the entire length of the oligomeric compound, or in a portion of the antisense compound (e.g., nucleobases 1-20 of a 27-mer may be compared to a 20-mer to determine percent identity of the oligomeric compound to the SEQ ID NO.) It is understood by those skilled in the art that an antisense compound need not have an identical sequence to those described herein to function similarly to the antisense compound described herein. Shortened versions of antisense compound taught herein, or non-identical versions of the antisense compound taught herein fall within the scope of the invention. Non-identical versions are those wherein each base does not have the same pairing activity as the antisense compounds disclosed herein. Bases do not have the same pairing activity by being shorter or having at least one abasic site. Alternatively, a non-identical version can include at least one base replaced with a different base with different pairing activity (e.g., G can be replaced by C, A, or T). Percent identity is calculated according to the number of bases that have identical base pairing corresponding to the SEQ ID NO or antisense compound to which it is being compared. The non-identical bases may be adjacent to each other, dispersed through out the oligonucleotide, or both.

For example, a 16-mer having the same sequence as nucleobases 2-17 of a 20-mer is 80% identical to the 20-mer. Alternatively, a 20-mer containing four nucleobases not identical to the 20-mer is also 80% identical to the 20-mer. A 14-mer having the same sequence as nucleobases 1-14 of an 18-mer is 78% identical to the 18-mer. Such calculations are well within the ability of those skilled in the art.

The percent identity is based on the percent of nucleobases in the original sequence present in a portion of the modified sequence. Therefore, a 30 nucleobase antisense compound comprising the full sequence of the complement of a 20 nucleobase active target segment would have a portion of 100% identity with the complement of the 20 nucleobase active target segment, while further comprising an additional 10 nucleobase portion. In the context of the invention, the complement of an active target segment may constitute a single portion. In a preferred embodiment, the oligonucleotides of the instant invention are at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most prefereably at least 95% identical to at least a portion of the complement of the active target segments presented herein.

It is well known by those skilled in the art that it is possible to increase or decrease the length of an antisense compound and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992, incorporated herein by reference), a series of ASOs 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model. ASOs 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the ASOs were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the ASOs that contained no mismatches. Similarly, target specific cleavage was achieved using a 13 nucleobase ASOs, including those with 1 or 3 mismatches. Maher and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988, incorporated herein by reference) tested a series of tandem 14 nucleobase ASOs, and a 28 and 42 nucleobase ASOs comprised of the sequence of two or three of the tandem ASOs, respectively, for their ability to arrest translation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase ASOs alone were able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase ASOs.

Therapeutics

Modulators of PTPRU, more preferably selective modulators of PTPRU and more preferably still antisense compounds can be used to modulate the expression of PTPRU in an animal, such as a human. Modulation of PTPRU is herein disclosed as resulting in a corresponding modulation in glucose levels, therefore there are provided compositions and methods for treating conditions and disorders associated with blood glucose levels. In one non-limiting embodiment, the methods comprise the step of administering to said animal in need of therapy for a disease or condition associated with PTPRU an effective amount of an antisense compound that inhibits expression of PTPRU. A disease or condition associated with PTPRU includes, but is not limited to, diabetes, type II diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease. The diseases or conditions are associated with clinical indicators that include, but are not limited to blood glucose levels, blood lipid levels, hepatic lipid levels, insulin levels, cholesterol levels, transaminase levels, electrocardiogram, glucose uptake, gluconeogenesis, insulin sensitivity, body weight and combinations thereof. In one embodiment, the antisense compounds of the present invention effectively inhibit the levels or function of PTPRU mRNA. Because reduction in PTPRU mRNA levels can lead to alteration in PTPRU protein products of expression as well, such resultant alterations can also be measured. Antisense compounds of the present invention that effectively inhibit the level or function of PTPRU mRNA or protein products of expression are considered an active antisense compounds. In one embodiment, the antisense compounds of the invention inhibit the expression of PTPRU causing a reduction of RNA by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100%.

For example, the reduction of the expression of PTPRU can be measured in a bodily fluid, tissue or organ of the animal. Methods of obtaining samples for analysis, such as body fluids (e.g., blood), tissues (e.g., biopsy), or organs, and methods of preparation of the samples to allow for analysis are well known to those skilled in the art. Methods for analysis of RNA and protein levels are discussed above and are well known to those skilled in the art. The effects of treatment can be assessed by measuring biomarkers associated with the PTPRU expression in the aforementioned fluids, tissues or organs, collected from an animal contacted with one or more compounds of the invention, by routine clinical methods known in the art. These biomarkers include but are not limited to: liver transaminases, bilirubin, albumin, blood urea nitrogen, creatine and other markers of kidney and liver function; glucose levels, triglyceride levels, insulin levels, fatty acid levels, cholesterol levels, electrocardiogram, glucose uptake, gloconeogenesis, insulin sensitivity and body weight, and other markers of diabetes, type II diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease. Additionally, the effects of reatment can be assessed using non-invasive indicators of improved disease state or condition, such as electrocardiogram, body weight, and the like.

The antisense compounds of the present invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Acceptable carriers and dilutents are well known to those skilled in the art. Selection of a dilutent or carrier is based on a number of factors, including, but not limited to, the solubility of the compound and the route of administration. Such considerations are well understood by those skilled in the art. In one aspect, the compounds of the present invention inhibit the expression of PTPRU. The compounds of the invention can also be used in the manufacture of a medicament for the treatment of diseases and disorders related to PTPRU expression by restoring glucose levels, triglyceride levels, insulin levels, fatty acid levels, cholesterol levels, glucose uptake, gloconeogenesis and insulin sensitivity to non-diesase state profiles. Moreover, the compounds of the invention can be used in the manufacture of a medicament for the modulation of blood glucose levels. In this aspect, the compound is preferably a modulator that is specific for PTPRU, and is more preferably an antisense compound that inhibits the expression of a nucleic acid that encodes PTPRU. Also in this aspect, the medicament is used to modulate blood glucose levels and treat diseases and conditions associated therewit. Disease and conditions associated with dysregulated blood glucose levels include, but are not limited to, diabetes, type II diabetes, prediabetes, obesity, metabolic syndrome or a combination thereof.

Methods whereby bodily fluids, organs or tissues are contacted with an effective amount of one or more of the antisense compounds or compositions of the invention are also contemplated. Bodily fluids, organs or tissues can be contacted with one or more of the compounds of the invention resulting in modulation of PTPRU expression in the cells of bodily fluids, organs or tissues.

Kits, Research Reagents, and Diagnostics

The antisense compounds of the present invention can be utilized for diagnostics, and as research reagents and kits. Furthermore, antisense compounds, which are able to inhibit gene expression with specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues. Methods of gene expression analysis are well known to those skilled in the art.

Antisense Compounds

The term “antisense compound” refers to a polymeric structure capable of hybridizing to a region of a nucleic acid molecule. As is also used herein, the term “active antisense compound” is an antisense compound that has been determined to hybridize with the target nucleic acid and modulate its expression. Generally, antisense compounds comprise a plurality of monomeric subunits linked together by internucleoside linking groups and/or internucleoside linkage mimetics. Each of the monomeric subunits comprises a sugar, abasic sugar, modified sugar, or a sugar mimetic, and except for the abasic sugar, includes a nucleobase, modified nucleobase or a nucleobase mimetic. Preferred monomeric subunits comprise nucleosides and modified nucleosides. An antisense compound is at least partially complementary to the region of a target nucleic acid molecule to which it hybridizes and which modulates (increases or decreases) its expression. This term includes oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide inimetics, antisense compounds, antisense oligomeric compounds, and chimeric combinations of these. An “antisense oligonucleotide” is an antisense compound that is a nucleic acid-based oligomer. An antisense oligonucleotide can, in some cases, include one or more chemical modifications to the sugar, base, and/or internucleoside linkages. Nonlimiting examples of antisense compounds include antisense compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, and siRNAs. As such, these compounds can be introduced in the form of single-stranded, double-stranded, circular, branched or hairpins and can contain structural elements such as internal or terminal bulges or loops. In some embodiments it is desirous to take advantage of alternate antisense mechanisms (such as RNAi). Antisense compounds that use these alternate mechanisms may optionally comprise a second compound which is complementary to the antisense compound. In other words, antisense double-stranded compounds can be two strands hybridized to form double-stranded compounds or a single strand with sufficient self complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. The compounds of the instant invention are not auto-catalytic. As used herein, “auto-catalytic” means a compound has the ability to promote cleavage of the target RNA in the absence of accessory factors, e.g. proteins.

In one embodiment of the invention, double-stranded antisense compounds encompass short interfering RNAs (siRNAs). As used herein, the term “siRNA” is defined as a double-stranded compound having a first and second strand, each strand having a central portion and two independent terminal portions. The central portion of the first strand is complementary to the central portion of the second strand, allowing hybridization of the strands. The terminal portions are independently, optionally complementary to the corresponding terminal portion of the complementary strand. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang

Each strand of the siRNA duplex may be from about 12 to about 35 nucleobases. In a preferred embodiment, each strand of the siRNA duplex is about 17 to about 25 nucleobases. The two strands may be fully complementary (i.e., form a blunt ended compound), or include a 5′ or 3′ overhang on one or both strands. Double-stranded compounds can be made to include chemical modifications as discussed herein.

In one embodiment of the invention, the antisense compound comprises a single stranded oligonucleotide. In some embodiments of the invention the antisense compound contains chemical modifications. In a preferred embodiment, the antisense compound is a single stranded, chimeric oligonucleotide wherein the modifications of sugars, bases, and internucleoside linkages are independently selected.

The antisense compounds may comprise a length from about 12 to about 35 nucleobases (i.e. from about 12 to about 35 linked nucleosides). In other words, a single-stranded compound of the invention comprises from about 12 to about 35 nucleobases, and a double-stranded antisense compound of the invention (such as a siRNA, for example) comprises two strands, each of which is independently from about 12 to about 35 nucleobases. This includes oligonucleotides 15 to 35 and 16 to 35 nucleobases in length. Contained within the antisense compounds of the invention (whether single or double stranded and on at least one strand) are antisense portions. The “antisense portion” is that part of the antisense compound that is designed to work by one of the aforementioned antisense mechanisms. One of ordinary skill in the art will appreciate that about 12 to about 35 nucleobases includes 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nucleobases. For convenience we describe antisense compounds, but one ordinarily skilled in the art will understand that analogues and mimetics can have a length within this same range.

The oligomeric compounds in accordance with this invention may comprise a complementary oligomeric compound from about 13 to about 80 nucleobases (i.e. from about 13 to about 80 linked nucleosides). In other words, a single-stranded compound of the invention comprises from 13 to about 80 nucleobases, and a double-stranded antisense compound of the invention (such as a siRNA, for example) comprises two strands, each of which is from about 13 to about 80 nucleobases. Contained within the oligomeric compounds of the invention (whether single or double stranded and on at least one strand) are antisense portions. The “antisense portion” is that part of the oligomeric compound that is designed to work by an antisense mechanism. One of ordinary skill in the art will appreciate that this comprehends antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases. In one embodiment, the oligomeric compounds of the invention have antisense portions of 13 to 50 nucleobases. One having ordinary skill in the art will appreciate that this embodies oligomeric compounds having antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases. In one embodiment, the oligomeric compounds of the invention have antisense portions of 13 to 30 nucleobases. One having ordinary skill in the art will appreciate that this embodies oligomeric compounds having antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleobases. In some embodiments, the oligomeric compounds of the invention have antisense portions of 13 to 24 nucleobases. One having ordinary skill in the art will appreciate that this embodies oligomeric compounds having antisense portions of 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleobases.

Antisense compounds about 12 to 35 nucleobases in length, preferably about 15 to 35 nucleobases in length, comprising a stretch of at least eight (8), preferably at least 12, more preferably at least 15 consecutive nucleobases selected from within the active target regions are considered to be suitable antisense compounds as well.

Modifications can be made to the antisense compounds of the instant invention and may include conjugate groups attached to one of the termini, selected nucleobase positions, sugar positions or to one of the internucleoside linkages. Possible modifications include, but are not limited to, 2′-fluoro (2′-F), 2′-OMethyl (2′-OMe), 2′-Methoxy ethoxy (2′-MOE) sugar modifications, inverted abasic caps, deoxynucleobases, and bicyclice nucleobase analogs such as locked nucleic acids (LNA.sup.TM) and ENA.

Chemical Modifications

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base (sometimes referred to as a “nucleobase” or simply a “base”). The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2′, 3′ or 5′ hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′ to 5′ phosphodiester linkage. It is often preferable to include chemical modifications in oligonucleotides to alter their activity. Chemical modifications can alter oligonucleotide activity by, for example: increasing affinity of an antisense oligonucleotide for its target RNA, increasing nuclease resistance, and/or altering the pharmacokinetics of the oligonucleotide. The use of chemistries that increase the affinity of an oligonucleotide for its target can allow for the use of shorter oligonucleotide compounds.

The term “nucleobase” or “heterocyclic base moiety” as used herein, refers to the heterocyclic base portion of a nucleoside. In general, a nucleobase is any group that contains one or more atom or groups of atoms capable of hydrogen bonding to a base of another nucleic acid. In addition to “unmodified” or “natural” nucleobases such as the purine nucleobases adenine (A) and guanine (G), and the pyrimidine nucleobases thymine (T), cytosine (C) and uracil (U), many modified nucleobases or nucleobase mimetics known to those skilled in the art are amenable to the present invention. The terms modified nucleobase and nucleobase mimetic can overlap but generally a modified nucleobase refers to a nucleobase that is fairly similar in structure to the parent nucleobase, such as for example a 7-deaza purine or a 5-methyl cytosine, whereas a nucleobase mimetic would include more complicated structures, such as for example a tricyclic phenoxazine nucleobase mimetic. Methods for preparation of the above noted modified nucleobases are well known to those skilled in the art.

Antisense compounds may also contain one or more nucleosides having modified sugar moieties. The furanosyl sugar ring of a nucleoside can be modified in a number of ways including, but not limited to, addition of a substituent group, bridging of two non-geminal ring atoms to form a bicyclic nucleic acid (BNA) and substitution of an atom or group such as —S—, —N(R)— or —C(R₁)(R₂) for the ring oxygen at the 4′-position. Modified sugar moieties are well known and can be used to alter, typically increase, the affinity of the antisense compound for its target and/or increase nuclease resistance. A representative list of preferred modified sugars includes but is not limited to bicyclic modified sugars (BNA's), including LNA and ENA (4′-(CH₂)₂—O-2′ bridge); and substituted sugars, especially 2′-substituted sugars having a 2′-F, 2′-OCH₂or a 2′-O(CH₂)₂—OCH₃substituent group. Sugars can also be replaced with sugar mimetic groups among others. Methods for the preparations of modified sugars are well known to those skilled in the art.

Internucleoside linking groups link the nucleosides or otherwise modified monomer units together thereby forming an antisense compound. The two main classes of internucleoside lnking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Representative non-phosphorus containing internucleoside linking groups include, but are not limited to, methylenemethylimino (—CH.sub.2-N(CH.sub.3)-O—CH.sub.2-), thiodiester (—O—C(O)—S—), thionocarbamate (—O—C(O)(NH)—S—); siloxane (—O—Si(H).sub.2-O—); and N,N′-dimethylhydrazine (—CH.sub.2-N(CH.sub.3)-N(CH.sub.3)-). Antisense compounds having non-phosphorus internucleoside linking groups are referred to as oligonucleosides. Modified internucleoside linkages, compared to natural phosphodiester linkages, can be used to alter, typically increase, nuclease resistance of the antisense compound. Internucleoside linkages having a chiral atom can be prepared racemic, chiral, or as a mixture. Representative chiral internucleoside linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known to those skilled in the art.

As used herein the term “mimetic” refers to groups that are substituted for a sugar, a nucleobase, and/or internucleoside linkage. Generally, a mimetic is used in place of the sugar or sugar-internucleoside linkage combination, and the nucleobase is maintained for hybridization to a selected target. Representative examples of a sugar mimetic include, but are not limited to, cyclohexenyl or morpholino. Representative examples of a mimetic for a sugar-internucleoside linkage combination include, but are not limited to, peptide nucleic acids (PNA) and morpholino groups linked by uncharged achiral linkages. In some instances a mimetic is used in place of the nucleobase. Representative nucleobase mimetics are well known in the art and include, but are not limited to, tricyclic phenoxazine analogs and universal bases (Berger et al., Nuc Acid Res. 2000, 28:2911-14, incorporated herein by reference). Methods of synthesis of sugar, nucleoside and nucleobase mimetics are well known to those skilled in the art.

As used herein the term “nucleoside” includes, nucleosides, abasic nucleosides, modified nucleosides, and nucleosides having mimetic bases and/or sugar groups.

In the context of this disclosure, the term “oligonucleotide” refers to an oligomeric compound which is an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). This term includes oligonucleotides composed of naturally- and non-naturally-occurring nucleobases, sugars and covalent internucleoside linkages, possibly further including non-nucleic acid conjugates.

Provided are compounds having reactive phosphorus groups useful for forming internucleoside linkages including for example phosphodiester and phosphorothioate internucleoside linkages. Methods of preparation and/or purification of precursors or antisense compounds of the instant invention are not a limitation of the compositions or methods of the invention. Methods for synthesis and purification of DNA, RNA, and the antisense compounds are well known to those skilled in the art.

As used herein the term “chimeric antisense compound” refers to an antisense compound, having at least one sugar, nucleobase and/or internucleoside linkage that is differentially modified as compared to the other sugars, nucleobases and internucleoside linkages within the same oligomeric compound. The remainder of the sugars, nucleobases and internucleoside linkages can be independently modified or unmodified. In general a chimeric oligomeric compound will have modified nucleosides that can be in isolated positions or grouped together in regions that will define a particular motif. Any combination of modifications and or mimetic groups can comprise a chimeric oligomeric compound.

Chimeric antisense compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligomeric compound may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of inhibition of gene expression. Consequently, comparable results can often be obtained with shorter antisense compounds when chimeras are used, compared to for example phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Certain chimeric as well as non-chimeric antisense compounds can be further described as having a particular motif. As used herein, the term “motif” refers to the orientation of modified sugar moieties and/or sugar mimetic groups in an antisense compound relative to like or differentially modified or unmodified nucleosides. As used herein, the terms “sugars”, “sugar moieties” and “sugar mimetic groups’ are used interchangeably. Such motifs include, but are not limited to, gapped motifs, alternating motifs, fully modified motifs, hemimer motifs, blockmer motifs, and positionally modified motifs. The sequence and the structure of the nucleobases and type of internucleoside linkage is not a factor in determining the motif of an antisense compound.

As used herein, the term “gapped motif” refers to an antisense compound comprising a contiguous sequence of nucleosides that is divided into 3 regions, an internal region (gap) flanked by two external regions (wings). The regions are differentiated from each other at least by having differentially modified sugar groups that comprise the nucleosides. In some embodiments, each modified region is uniformly modified (e.g. the modified sugar groups in a given region are identical); however, other motifs can be applied to regions. For example, the wings in a gapmer could have an alternating motif. The nucleosides located in the gap of a gapped antisense compound have sugar moieties that are different than the modified sugar moieties in each of the wings.

As used herein, the term “alternating motif” refers to an antisense compound comprising a contiguous sequence of nucleosides comprising two differentially sugar modified nucleosides that alternate for essentially the entire sequence of the antisense compound, or for essentially the entire sequence of a region of an antisense compound.

As used herein, the term “fully modified motif” refers to an antisense compound comprising a contiguous sequence of nucleosides wherein essentially each nucleoside is a sugar modified nucleoside having uniform modification.

As used herein, the term “hemimer motif” refers to a sequence of nucleosides that have uniform sugar moieties (identical sugars, modified or unmodified) and wherein one of the 5′-end or the 3′-end has a sequence of from 2 to 12 nucleosides that are sugar modified nucleosides that are different from the other nucleosides in the hemimer modified antisense compound.

As used herein, the term “blockmer motif” refers to a sequence of nucleosides that have uniform sugars (identical sugars, modified or unmodified) that is internally interrupted by a block of sugar modified nucleosides that are uniformly modified and wherein the modification is different from the other nucleosides. Methods of preparation of chimeric oligonucleotide compounds are well known to those skilled in the art.

As used herein, the term “positionally modified motif” comprises all other motifs. Methods of preparation of positionally modified oligonucleotide compounds are well known to those skilled in the art.

The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), alpha. or beta., or as (D) or (L) such as for amino acids et al. This is meant to include all such possible isomers, as well as their racemic and optically pure forms.

In one aspect, antisense compounds are modified by covalent attachment of one or more conjugate groups. Conjugate groups may be attached by reversible or irreversible attachments. Conjugate groups may be attached directly to antisense compounds or by use of a linker. Linkers may be mono- or bifunctional linkers. Such attachment methods and linkers are well known to those skilled in the art. In general, conjugate groups are attached to antisense compounds to modify one or more properties. Such considerations are well known to those skilled in the art.

Oligomer Synthesis

Oligomerization of modified and unmodified nucleosides can be routinely performed according to literature procedures for DNA (Protocols for Oligonucleotides and Analogs, Ed. Agrawal (1993), Humana Press) and/or RNA (Scaringe, Methods (2001), 23, 206-217. Gait et al., Applications of Chemically synthesized RNA in RNA: Protein Interactions, Ed. Smith (1998), 1-36. Gallo et al., Tetrahedron (2001), 57, 5707-5713).

Antisense compounds can be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives. The invention is not limited by the method of antisense compound synthesis.

Oligomer Purification and Analysis

Methods of oligonucleotide purification and analysis are known to those skilled in the art. Analysis methods include capillary electrophoresis (CE) and electrospray-mass spectroscopy. Such synthesis and analysis methods can be performed in multi-well plates. The compositions and methods disclosed herein not limited by the method of oligomer purification.

Salts, Prodrugs and Bioequivalents

The antisense compounds may comprise any pharmaceutically acceptable salts, esters, or salts of such esters, or any other functional chemical equivalent which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the antisense compounds, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term “prodrug” indicates a therapeutic agent that is prepared in an inactive or less active form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes, chemicals, and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE ((S-acetyl-2-thioethyl) phosphate) derivatives according to the methods disclosed in WO 93/24510 or WO 94/26764. Prodrugs can also include antisense compounds wherein one or both ends comprise nucleobases that are cleaved (e.g., phosphodiester backbone linkages) to produce the smaller active compound.

The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the antisense compounds: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. Sodium salts of antisense oligonucleotides are useful and are well accepted for therapeutic administration to humans. In another embodiment, sodium salts of dsRNA compounds are also provided.

Formulations

The antisense compounds may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds.

The antisense compounds may also include pharmaceutical compositions and formulations. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated.

The pharmaceutical formulations, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, finely divided solid carriers, or both, and then, if necessary, shaping the product (e.g., into a specific particle size for delivery).

A “pharmaceutical carrier” or “excipient” can be a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal and are known in the art. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition.

Combinations

Compositions provided herein can contain two or more antisense compounds. In another related embodiment, compositions can contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Alternatively, compositions can contain two or more antisense compounds targeted to different regions of the same nucleic acid target. Two or more combined compounds may be used together or sequentially. Compositions of the instant invention can also be combined with other non-antisense compound therapeutic agents.

Nonlimiting Disclosure and Incorporation by Reference

While certain compounds, compositions and methods have been described with specificity in accordance with certain embodiments, the following examples serve only as illustrations of the compounds and methods and are not intended to limit the claims of the invention. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.

EXAMPLE 1 Cell Types and Transfection Methods

Cell types—The effect of antisense compounds on target nucleic acid expression was tested in one or more of the following cell types.

A549: The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (Manassas, Va.). A549 cells were routinely cultured in DMEM, high glucose (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum, 100 units per ml penicillin, and 100 micrograms per ml streptomycin (Invitrogen Life Technologies, Carlsbad, Calif.). Cells were routinely passaged by trypsimization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 5000 cells/well for use in oligomeric compound transfection experiments.

B16-F10: The mouse melanoma cell line B16-F10 was obtained from the American Type Culture Collection (Manassas, Va.). B16-F10 cells were routinely cultured in DMEM, high glucose (Invitrogen Life Technologies, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Carlsbad, Calif.), Cells were routinely passaged by trypsinization and dilution when they reached approximately 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of approximately 6500 cells/well for use in oligomeric compound transfection experiments.

RAW264.7: The mouse Abelson murine leukemia virus-induced tumor macrophage cell line is obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). RAW 264.7 cells are routinely cultured in alpha-MEM (Invitrogen Corporation, Carlsbad, Calif.) supplemented with 10% fetal bovine serum (Invitrogen Corporation, Carlsbad, Calif.), penicillin 100 units per mL, and streptomycin 100 .micro.g/mL (Invitrogen Corporation, Carlsbad, Calif.). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence. Cells are seeded into 24-well plates (Falcon-353047) at a density of ˜20,000 cells/cm2 for treatment with the oligomeric compounds of the invention.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds: When cells reach appropriate confluency, they are treated with 50 nM of oligonucleotide using Lipofectin™. When cells reached 65-75% confluency, they were treated with oligonucleotide. Oligonucleotide was mixed with LIPOFECTIN™ (Invitrogen Life Technologies, Carlsbad, Calif.) in Opti-MEM™-1 reduced serum medium (Invitrogen Life Technologies, Carlsbad, Calif.) to achieve the desired concentration of oligonucleotide and a LIPOFECTIN™ concentration of 2.5 or 3 .micro.g/mL per 100 nM oligonucleotide. Final concentration of the oligonucleotide was 50 nM. This transfection mixture was incubated at room temperature for approximately 0.5 hours. For cells grown in 96-well plates, wells were washed once with 100 .micro.L OPTI-MEM™-1 and then treated with 130 .micro.L of the transfection mixture. Cells grown in 24-well plates or other standard tissue culture plates are treated similarly, using appropriate volumes of medium and oligonucleotide. Cells are treated and data are obtained in duplicate or triplicate. After approximately 4-7 hours of treatment at 37 .deg.C, the medium containing the transfection mixture was replaced with fresh culture medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

Control Oligonucleotides

Control oligonucleotides are used to determine the optimal oligomeric compound concentration for a particular cell line. Furthermore, when antisense compounds of the invention are tested in oligomeric compound screening experiments or phenotypic assays, control oligonucleotides are tested in parallel with compounds of the invention.

The concentration of oligonucleotide used will vary from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. The concentration of positive control oligonucleotide that results in 80% inhibition of the target mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of the target mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 mM to 300 nM when the antisense oligonucleotide is transfected using a liposome reagent and 1 .micro.M to 40 .micro.M when the antisense oligonucleotide is transfected by electroporation. Representative control oligos are presented in table 17.

TABLE 17

Control oligonucleotides for cell line testing, oligomeric
compound screening and phenotypic assays

					SEQ
		Species of			ID
Compound #	Target Name	Target	Sequence (5′ to 3′)	Motif	NO

113131	CD86	Human	CGTGTGTCTGTGCTAGTCCC	5-10-5	6

289865	forkhead	Human	GGCAACGTGAACAGGTCCAA	5-10-5	7
	box O1A
	(rhabdomyos-
	arcoma)

25237	integrin beta	Human	GCCCATTGCTGGACATGC	4-10-4	8
	3

196103	integrin beta	Human	AGCCCATTGCTGGACATGCA	5-10-5	9
	3

148715	Jagged 2	Human;	TTGTCCCAGTCCCAGGCCTC	5-10-5	10
		Mouse;
		Rat

18076	Jun-N	Human	CTTTC^uCGTTGGA^uC^uCCCTGGG	5-9-6	11
	Terminal
	Kinase-1

18078	Jun N-	Human	GTGCG^uCG^uCGAG^uC^uC^uCGAAATC	5-9-6	12
	Terminal
	Kinase-2

183881	kinesin-like 1	Human	ATCCAAGTGCTACTGTAGTA	5-10-5	13

29848	none	none	NNNNNNNNNNNNNNNNNNNN	5-10-5	14

226844	Notch	Human;	GCCCTCCATGCTGGCACAGG	5-10-5	15
	(Drosophila)	Mouse
	homolog 1

105990	Peroxisome	Human	AGCAAAAGATCAATCCGTTA	5-10-5	16
	proliferator
	activated
	receptor
	gamma

336806	Raf kinase C	Human	TACAGAAGGCTGGGCCTTGA	5-10-5	17

15770	Raf kinase C	Mouse;	ATGCATT^uCTG^uC^uC^uC^uC^uCAAGGA	5-10-5	18
		Murine
		sarcoma
		virus;
		Rat

141923	None	None	CCTTCCCTGAAGGTTCCTCC	5-10-5	138

129700	None	None	TAGTGCGGACCTACCCACGA	5-10-5	139

EXAMPLE 2 Real-Time Quantitative PCR Analysis of PTPRU mRNA Levels

Quantitation of PTPRU mRNA levels was accomplished by real-time quantitative PCR using the ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer's instructions.

Prior to quantitative PCR analysis, primer-probe sets specific to the PTPRU being measured were evaluated for their ability to be “multiplexed” with a GAPDH amplification reaction. After isolation the RNA is subjected to sequential reverse transcriptase (RT) reaction and real-time PCR, both of which are performed in the same well. RT and PCR reagents were obtained from Invitrogen Life Technologies (Carlsbad, Calif.). RT, real-time PCR was carried out in the same by adding 20 .micro.L PCR cocktail (2.5×PCR buffer minus MgCl.sub.2, 6.6 mM MgCl.sub.2, 375 micro. M each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5×ROX dye) to 96-well plates containing 30 .micro.L total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48 .deg.C. Following a 10 minute incubation at 95 .deg.C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95 .deg.C for 15 seconds (denaturation) followed by 60 .deg.C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by RT, real-time PCR were normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, Oreg.). GAPDH expression was quantified by RT, real-time PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA was quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, Oreg.).

170 .micro.L of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5) was pipetted into a 96-well plate containing 30 .micro.L purified cellular RNA. The plate was read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485 nm and emission at 530 nm.

The GAPDH PCR probes have JOE covalently linked to the 5′ end and TAMRA or MGB covalently linked to the 3′ end, where JOE is the fluorescent reporter dye and TAMRA or MGB is the quencher dye. In some cell types, primers and probe designed to a GAPDH sequence from a different species are used to measure GAPDH expression. For example, a human GAPDH primer and probe set is used to measure GAPDH expression in monkey-derived cells and cell lines.

Probes and primers for use in real-time PCR were designed to hybridize to target-specific sequences. The primers and probes and the target nucleic acid sequences to which they hybridize are presented in Table 2. The target-specific PCR probes have FAM covalently linked to the 5′ end and TAMRA or MGB covalently linked to the 3′ end, where FAM is the fluorescent dye and TAMRA or MGB is the quencher dye.

TABLE 2

PTPRU-specific primers and probes for use in real-time PCR

	Target			SEQ
	SEQ ID	Sequence		ID
Species	NO	Description	Sequence (5′ to 3′)	NO

Human	1, 2 & 4	Fwd Primer	GAGCCTGAGCGAGAATGATAGC	32

Human	1, 2 & 4	Rev Primer	GGGATCCAGTCATATTCCACACA 33

Human	1, 2 & 4	Probe	FAM-CGTCTACGTGCGCGTTAATGG-TAMRA	34

Mouse	5	Fwd Primer	GCCCAGAAAGGCCTATCTCAT	35

Mouse	5	Rev Primer	GCAATTCGGATGCAGTTCAGT	36

Mouse	5	Probe	FAM-AGGCAGCAAGCCACCTGAAAGGG-TAMRA	37

EXAMPLE 3 Antisense Inhibition of Human PTPRU Expression by Antisense Compounds

A series of antisense compounds was designed to target different regions of human PTPRU RNA, using published sequences or portions of published sequences as cited in Table 1. The designed antisense compounds are complementary to one or more of the target nucleic acids in Table 1. The start and stop sites on the target nucleic acids for each antisense compound are presented in Tables 3a, b and c.

TABLE 3a

SEQ ID NO 1

	Start	Stop
Compound #	Site	Site

356182	128	147
284985	206	225
284986	211	230
284987	431	450
284988	436	455
284989	441	460
284990	545	564
284991	550	569
284992	555	574
284993	560	579
284994	565	584
284995	570	589
284996	610	629
284997	615	634
284998	1046	1065
284999	1051	1070
285000	1056	1075
285001	1062	1081
285002	1150	1169
285003	1304	1323
285004	1422	1441
285005	1471	1490
285006	1619	1638
285007	1624	1643
285008	1691	1710
356183	1892	1911
285009	1901	1920
285010	1906	1925
285011	1911	1930
285012	1916	1935
348393	2179	2198
285019	2348	2367
285020	2353	2372
285021	2378	2397
285022	2429	2448
285023	2434	2453
356184	2445	2464
285025	2513	2532
285026	2549	2568
285027	2669	2688
285030	2990	3009
285031	2995	3014
285032	3000	3019
285033	3006	3025
285034	3087	3106
285036	3224	3243
285037	3278	3297
285038	3359	3378
285039	3364	3383
285040	3422	3441
285041	3429	3448
285043	3566	3585
285044	3571	3590
285045	3576	3595
285046	3845	3864
285047	3872	3891
285048	3915	3934
285049	3974	3993
285050	4220	4239
285051	4358	4377
356185	4405	4424
356186	4467	4486
356187	5114	5133
356188	5359	5378
285054	5505	5524
285055	5510	5529
285056	5515	5534
285057	5520	5539
356189	5584	5603

TABLE 3b

SEQ ID NO: 2

	Start	Stop
Compound #	Site	Site

356182	128	147
284985	206	225
284986	211	230
284987	431	450
284988	436	455
284989	441	460
284990	545	564
284991	550	569
284992	555	574
284993	560	579
284994	565	584
284995	570	589
284996	610	629
284997	615	634
284998	1046	1065
284999	1051	1070
285000	1056	1075
285001	1062	1081
285002	1150	1169
285003	1304	1323
285004	1422	1441
285005	1471	1490
285006	1619	1638
285007	1624	1643
285008	1691	1710
356183	1892	1911
285009	1901	1920
285010	1906	1925
285011	1911	1930
285012	1916	1935
348393	2179	2198
285019	2348	2367
285020	2353	2372
285021	2378	2397
285022	2429	2448
285023	2434	2453
356173	2445	2464
285025	2483	2502
285026	2519	2538
285027	2639	2658
285030	2978	2997
285031	2983	3002
285032	2988	3007
285033	2994	3013
285034	3075	3094
285036	3212	3231
285037	3266	3285
285038	3347	3366
285039	3352	3371
285040	3410	3429
285041	3417	3436
285043	3554	3573
285044	3559	3578
285045	3564	3583
285046	3833	3852
285047	3860	3879
285048	3903	3922
285049	3962	3981
285050	4202	4221
285051	4340	4359
356185	4387	4406
356186	4449	4468
356187	5096	5115
356188	5340	5359
285054	5486	5505
285055	5491	5510
285056	5496	5515
285057	5501	5520
356189	5565	5584

TABLE 3c

SEQ ID NO: 4

	Start	Stop
Compound #	Site	Site

356182	525	544
284986	19165	19184
284987	22483	22502
284988	22488	22507
284989	22493	22512
284990	22597	22616
284991	22602	22621
284992	22607	22626
284993	22612	22631
284994	22617	22636
284995	22622	22641
284997	23151	23170
284998	24558	24577
284999	24563	24582
285000	24568	24587
285001	24574	24593
285002	24662	24681
285003	39360	39379
285004	39478	39497
285005	39527	39546
285006	42930	42949
285007	42935	42954
285009	43927	43946
285010	43932	43951
285011	43937	43956
285012	43942	43961
348393	46739	46758
285019	48652	48671
285020	48657	48676
285021	48682	48701
285022	48733	48752
285023	48738	48757
356174	53552	53571
356175	53562	53581
356176	53592	53611
285025	55786	55805
285026	55822	55841
356177	56678	56697
285027	67770	67789
285030	74636	74655
285031	74641	74660
285032	74646	74665
285034	75408	75427
285037	76480	76499
285038	76561	76580
285039	76566	76585
356178	76815	76834
356179	78188	78207
285040	79289	79308
285041	79296	79315
285043	79927	79946
285044	79932	79951
285045	79937	79956
285047	84592	84611
285048	84635	84654
285049	84694	84713
356180	87516	87535
285050	87619	87638
356181	87668	87687
285051	89159	89178
356186	89540	89559
356187	90187	90206
356188	90432	90451
285054	90578	90597
285055	90583	90602
285056	90588	90607
285057	90593	90612
356189	90657	90676

As stated above, antisense oligonucleotides directed to a target or more preferably to an active target segment can be from about 13 to about 80 linked nucleobases. The following Table 3d provides a non-limiting example of such antisense oligonucleotides targeting SEQ ID NO 1.

TABLE 3d

Antisense Oligonucleotides from about 13 to about
35 Nucleobases

Sequence	Length

CAGCCAGCTCAGCCTGGTGC	20 nucleobases	(SEQ ID NO: 48)

AGTGCTGACAGCCAG	15 nucleobases	(SEQ ID NO: 19)

GCTGACAGCCAGCTC	15 nucleobases	(SEQ ID NO: 20)

GTGCTGACAGCCA	13 nucleobases	(SEQ ID NO: 21)

AGTGCTGACAGCCAGCTCAGCCTG	24 nucleobases	(SEQ ID NO: 22)

GCCAGCTCAGCCTG	14 nucleobases	(SEQ ID NO: 23)

AGAAAGTGCTGACAGCCAGCTCAGCCTGGTGCCAC	35 nucleobases	(SEQ ID NO: 24)

CTGACAGCCAGCTCAGCCTGGTGCCAC	27 nucleobases	(SEQ ID NO: 25)

CAGCCAGCTCAGCCTGGTGCCAC	22 nucleobases	(SEQ ID NO: 26)

Antisense oligonucleotides directed to a target or more preferably to an active target segment can also contain mismatched nucleobases when compared to the target sequence. The following Table 3e provides a non-limiting example of such antisense oligonucleotides targeting nucleobases 565 to 584 of SEQ ID NO 1. Mismatched nucleobases are underlined. One ordinarily skilled in the art understands that antisense compounds can tolerate mismatches yet still retain their ability to hybridize with a target site and modulate the target nucleic acid through antisense mechanisms.

TABLE 3e

Antisense Oligonucleotides from about 1-3
Nucleobases Mismatched to the Target
Sequence

	Number of
	mismatches to
Sequence	SEQ ID NO: 1

CAGCCAGCTCAGCGTGGTGC	(SEQ ID NO: 48)	None

CAGCCAGCTCAGCCTGTTGC	(SEQ ID NO: 27)	One mismatch

CAGCCAGCTCAGCCTGGTGG	(SEQ ID NO: 28)	One mismatch

TTGCCAGCTCAGCCTGGTGC	(SEQ ID NO: 29)	Two mismatches

CAGGCAGCTCACCCTGGTGC	(SEQ ID NO: 30)	Two mismatches

CAGTCAGCACAGCCTTGTGC	(SEQ ID NO: 31)	Three
		mismatches

These antisense compounds were screened in vitro to determine the compound's ability to modulate expression of a target nucleic acid that encodes PTPRU. The compounds shown in Table 4 are all chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of 10 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′) by five-nucleotide “wings”. The wings are composed of 2′-O-(2-methoxyethyl) nucleotides, also known as 2′-MOE nucleotides. The internucleoside (backbone) linkages are phosphorothioate throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on gene target mRNA levels by quantitative real-time PCR as described in other examples herein, using the primer-probe set designed to hybridize to human PTPRU (Table 2). Data are averages from two experiments in which A549 cells were treated with 50 nM of the disclosed antisense compounds using LIPOFECTIN™. A reduction in expression is expressed as percent inhibition in Table 4. The control oligomeric compound used was SEQ ID NO: 12.

TABLE 4

Inhibition of human PTPRU mRNA levels by chimeric
oligonucleotides having 2′-MOE wings and deoxy gap

	Target				SEQ
Compound	SEQ ID	Target		%	ID
#	NO	Site	Sequence (5′ to 3′)	Inhibition	NO

356182	1	128	GCACGGGCCATGGTTGGAGC	53	38

284985	1	206	TCGAAGGTGCAGCCAGCTGC	62	39

284986	1	211	CCTCCTCGAAGGTGCAGCCA	81	40

284987	1	431	AAGTAGCTGAACTGCACACA	77	41

284988	1	436	ACAGGAAGTAGCTGAACTGC	81	42

284989	1	441	GCTGTACAGGAAGTAGCTGA	76	43

284990	1	545	CACTGACGGCCGTGGGATCC	62	44

284991	1	550	GGTGCCACTGACGGCCGTGG	66	45

284992	1	555	AGCCTGGTGCCACTGACGGC	73	46

284993	1	560	AGCTCAGCCTGGTGCCACTG	63	47

284994	1	565	CAGCCAGCTCAGCCTGGTGC	59	48

284995	1	570	GCTGACAGCCAGCTCAGCCT	79	49

284996	1	610	GGGCCTCAAACAGCACCTGA	77	50

284997	1	615	GATGAGGGCCTCAAACAGCA	57	51

284998	1	1046	GAGTTGGTGTTGAGCTGGAT	82	52

284999	1	1051	TGATGGAGTTGGTGTTGAGC	73	53

285000	1	1056	GCCAATGATGGAGTTGGTGT	80	54

285001	1	1062	CCCGTCGCCAATGATGGAGT	84	55

285002	1	1150	ACAGCTTGTAGGTCTGCAGG	50	56

285003	1	1304	TGGATCTCAGCAAAAGCCAG	57	57

285004	1	1422	GATGGTCTGGTTGTGGCTGC	77	58

285005	1	1471	TCTTGATGGTGTAGCGGCTG	80	59

285006	1	1619	TCCTCCAGTGGAGTGAAGGT	75	60

285007	1	1624	TCATGTCCTCCAGTGGAGTG	65	61

285008	1	1691	TGGTAGCTGATCTCATACTG	80	62

356183	1	1892	AAGCTGGGAGCAGAGATGTT	55	63

285009	1	1901	GCATAATCAAAGCTGGGAGC	80	64

285010	1	1906	TGTCGGCATAATCAAAGCTG	70	65

285011	1	1911	CGGCATGTCGGCATAATCAA	75	66

285012	1	1916	GGTGACGGCATGTCGGCATA	77	67

348393	1	2179	AGGTCTGGTTGTCACCCACG	72	68

285019	1	2348	TCCTCCGATCTCTGGGACAC	53	69

285020	1	2353	CCATCTCCTCCGATCTCTGG	74	70

285021	1	2378	CCTGCACAGATGCCCAGGAT	73	71

285022	1	2429	CGGATGATGACAATGATGGC	49	72

285023	1	2434	CTTTGCGGATGATGACAATG	54	73

356184	1	2445	GTGGTCTCTCCCTTTGCGGA	38	74

285025	1	2513	TTCTCCTGGCGGTAGTTGAC	40	75

285026	1	2549	GTGAAGCTGCGGTCCACGGC	76	76

285027	1	2669	CCCAGGAGGCTGCTGGCCTC	52	77

285030	1	2990	AAGTGGTTTGACCTGTGGTA	69	78

285031	1	2995	CTATGAAGTGGTTTGACCTG	34	79

285032	1	3000	AGTGGCTATGAAGTGGTTTG	76	80

285033	1	3006	CCCTTGAGTGGCTATGAAGT	61	81

285034	1	3087	CAGCTTGGTGATCATGACGA	55	82

285036	1	3224	CCTCTCCGCTCCAGGGCAAA	51	83

285037	1	3278	TGCTCTGGCCACGCTGTGAA	72	84

285038	1	3359	ATGGGCCCGGCATCAGGTGG	56	85

285039	1	3364	TGACAATGGGCCCGGCATCA	45	86

285040	1	3422	AGCATCACATCCAGGACGAT	48	87

285041	1	3429	CATGTCCAGCATCACATCCA	44	88

285043	1	3566	GTCTCCCCACACAGGCAGGC	71	89

285044	1	3571	TGGTGGTCTCCCCACACAGG	80	90

285045	1	3576	AGGGATGGTGGTCTCCCCAC	58	91

285046	1	3845	CGTGTGTAGCTGTCAGTCAG	53	92

285047	1	3872	TGCAGGGTCACGATGAAGGC	80	93

285048	1	3915	GTAGACCAGCCGCCAGAAGT	39	94

285049	1	3974	CAGGCGGAGTTGGACTGGTT	72	95

285050	1	4220	TGCCACTTGTCCACCTCAGC	56	96

285051	1	4358	GTTTTGGCAGCAAAGAAAAC	21	97

356185	1	4405	GGTACTGATCCATGGTCTCC	49	98

356186	1	4467	AGGGCCCCGCTATCTTGACT	55	99

356187	1	5114	GGTTCAGGGAAGCTCAGAGC	80	100

356188	1	5359	GTATGACCAGCCCTGCTCTA	46	101

285054	1	5505	ATCTACAGTTTACAGATGGG	51	102

285055	1	5510	GTCATATCTACAGTTTACAG	80	103

285056	1	5515	CAGTAGTCATATCTACAGTT	82	104

285057	1	5520	TAGGTCAGTAGTCATATCTA	63	105

356189	1	5584	GCACGTTTATTTACAAAGCG	85	106

356173	2	2445	CACCGGCTTCCCTTTGCGGA	56	107

356174	4	53552	CTGGCAGCGTGCAAAGAGAG	59	108

356175	4	53562	GTGGTCTCTCCTGGCAGCGT	73	109

356176	4	53592	AGCTACTTACGGGTAGTAGG	64	110

356177	4	56678	ATTTCAAGGGAATATTTACA	20	111

356178	4	76815	CCTCCTCAGCACCTGGGTCA	66	112

356179	4	78188	CAGCAATATCTCCTAAAGCT	55	113

356180	4	87516	GGTGCCCCTCCTGCAACTGG	67	114

356181	4	87668	AGGTACTCACAGGCAGTGCA	47	115

The screen identified active target segments within the human PTPRU mRNA sequence, specifically SEQ ID NO: 1, 2 and 4. Each active target segment was targeted by at least one active antisense oligonucleotide. These active target regions identified for SEQ ID NO: 1 include nucleotides nucleotides 1046 to 1081 (Region A) with an average inhibition of 79.7%, nucleotides 5510 to 5603 (Region B) with an average inhibition of 77.3%, nucleotides 431 to 629 (Region C) with an average inhibition of 71.5%, nucleotides 431 to 589 (Region D) with an average inhibition of 70.9%, nucleotides 431 to 460 (Region E) with an average inhibition of 78.0%, nucleotides 1422 to 1710 (Region F) with an average inhibition of 75.4%, nucleotides 1422 to 1490 (Region G) with an average inhibition of 78.4%, nucleotides 206 to 230 (Region H) with an average inhibition of 71.4%, nucleotides 1619 to 1710 (Region 1) with an average inhibition of 73.3% and nucleotides 1892 to 1935 (Region F) with an average inhibition of 71.4%. Each of the oligonucleotides tested within each of these regions inhibited expression of human PTPRU greater than 50% and over half of the oligonucleotides tested in this region inhibited expression by greater than 75%. Identification of these regions allows for the design of antisense oligonucleotides that modulate the expression of PTPRU.

The active target regions identified for SEQ ID NO: 2 include nucleotides nucleotides 1046 to 1081 (Region AA) with an average inhibition of 79.7%, nucleotides 5491 to 5584 (Region AB) with an average inhibition of 77.3%, nucleotides 206 to 230 (Region AC) with an average inhibition of 71.4%, nucleotides 431 to 589 (Region AD) with an average inhibition of 70.8%, nucleotides 431 to 460 (Region AE) with an average inhibition of 78.0%, nucleotides 431 to 579 (Region AF) with an average inhibition of 71.3%, nucleotides 1422 to 1490 (Region AG) with an average inhibition of 78.4%, nucleotides 1619 to 1710 (Region AH) with an average inhibition of 73.3% and nucleotides 1892 to 1935 (Region AI) with an average inhibition of 71.4%.

Active target regions have also been identified for SEQ ID NO: 4. These active target regions include nucleotides 24558 to 24593 (Region BA) with an average inhibition of 79.7%, nucleotides 90583 to 90676 (Region BB) with an average inhibition of 77.3%, nucleotides 22483 to 22641 (Region BC) with an average inhibition of 70.8%, nucleotides 22483 to 22616 (Region BD) with an average inhibition of 74.1%, nucleotides 43927 to 43961 (Region BE) with an average inhibition of 75.4%, and nucleotides 53552 to 53611 (Region BF) with an average inhibition of 65.3%.

EXAMPLE 4 Antisense Inhibition of Mouse PTPRU Expression by Antisense Compounds

A series of antisense compounds was designed to target different regions of mouse PTPRU, using published sequences cited in Table 1. The compounds are shown in Table 5. All compounds in Table 5 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of 10 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′) by five-nucleotide “wings”. The wings are composed of 2′-O-(2-methoxyethyl) nucleotides, also known as 2′-MOE nucleotides. The internucleoside (backbone) linkages are phosphorothioate throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on gene target mRNA levels by quantitative real-time PCR as described in other examples herein and using the mouse primers an probe from Table 2. Data are averages from two experiments in which B 16-F10 cells were treated with 150 nM of the disclosed antisense compounds using LIPOFECTIN™ (as described above). A reduction in expression is expressed as percent inhibition in Table 5. The control oligomeric compound used was SEQ ID NO: 12.

TABLE 5

Inhibition of mouse PTPRU mRNA levels by chimeric
oligonucleotides having 2′-MOE wings and deoxy gap

284981	5	108	CGCAACTGTATGTACCAAGC	12	116

284982	5	176	ATAGCAGTCGAACATTAATC	0	117

284983	5	225	TCGTTGGCATAGCTGACACC	0	118

284984	5	372	GAGCCCGGGCCATGGCCGCC	44	119

284985	5	448	TCGAAGGTGCAGCCAGCTGC	65	39

284986	5	453	CCTCCTCGAAGGTGCAGCCA	39	40

284987	5	673	AAGTAGCTGAACTGCACACA	56	41

284988	5	678	ACAGGAAGTAGCTGAACTGC	100	42

284989	5	683	GCTGTACAGGAAGTAGCTGA	63	43

284990	5	787	CACTGACGGCCGTGGGATCC	60	44

284991	5	792	GGTGCCACTGACGGCCGTGG	37	45

284992	5	797	AGCCTGGTGCCACTGACGGC	79	46

284993	5	802	AGCTCAGCCTGGTGCCACTG	51	47

284994	5	807	CAGCCAGCTCAGCCTGGTGC	68	48

284995	5	812	GCTGACAGCCAGCTCAGCCT	64	49

284996	5	852	GGGCCTCAAACAGCACCTGA	74	50

284997	5	857	GATGAGGGCCTCAAACAGCA	68	51

284999	5	1293	TGATGGAGTTGGTGTTGAGC	39	53

285000	5	1298	GCCAATGATGGAGTTGGTGT	63	54

285001	5	1304	CCCGTCGCCAATGATGGAGT	64	55

285002	5	1392	ACAGCTTGTAGGTCTGCAGG	67	56

285003	5	1546	TGGATCTCAGCAAAAGCCAG	71	57

285004	5	1664	GATGGTCTGGTTGTGGCTGC	53	58

285005	5	1713	TCTTGATGGTGTAGCGGCTG	60	59

285006	5	1861	TCCTCCAGTGGAGTGAAGGT	52	60

285007	5	1866	TCATGTCCTCCAGTGGAGTG	56	61

285008	5	1933	TGGTAGCTGATCTCATACTG	62	62

285009	5	2143	GCATAATCAAAGCTGGGAGC	71	64

285010	5	2148	TGTCGGCATAATCAAAGCTG	56	65

285011	5	2153	CGGCATGTCGGCATAATCAA	75	66

285012	5	2158	GGTGACGGCATGTCGGCATA	60	67

285013	5	2206	TGGGCCGGCCTCAACAGCAC	50	120

285014	5	2261	TGGCCGCTCTTCCTCCACAA	67	121

285015	5	2332	GCCAGGGCCGTCTCAAAGGT	79	122

285016	5	2387	CTCAAGCAGGCTGCTGGCAG	60	123

285017	5	2441	TGGGTTCCAGAAGCCACGAT	50	124

285018	5	2561	TCGCTTGCTCTCCTTGCACG	69	125

285019	5	2590	TCCTCCGATCTCTGGGACAC	40	69

285020	5	2595	CCATCTCCTCCGATCTCTGG	30	70

285021	5	2620	CCTGCACAGATGCCCAGGAT	64	71

285022	5	2671	CGGATGATGACAATGATGGC	24	72

285023	5	2676	CTTTGCGGATGATGACAATG	36	73

285024	5	2681	CTTCCCTTTGCGGATGATGA	58	126

285025	5	2725	TTCTCCTGGCGGTAGTTGAC	40	75

285026	5	2761	GTGAAGCTGCGGTCCACGGC	55	76

285027	5	2881	CCCAGGAGGCTGCTGGCCTC	44	77

285028	5	3027	TCTCGTACTCCTGCTTGAAG	49	127

285029	5	3103	TAGGCAGACACTGGCTCCTG	55	128

285030	5	3202	AAGTGGTTTGACCTGTGGTA	57	78

285031	5	3207	CTATGAAGTGGTTTGACCTG	33	79

285032	5	3212	AGTGGCTATGAAGTGGTTTG	42	80

285033	5	3218	CCCTTGAGTGGCTATGAAGT	38	81

285034	5	3299	CAGCTTGGTGATCATGACGA	51	82

285035	5	3377	CAGCGTGATCTTGATGTCCC	53	129

285036	5	3436	CCTCTCCGCTCCAGGGCAAA	17	83

285037	5	3490	TGCTCTGGCCACGCTGTGAA	26	84

285038	5	3571	ATGGGCCCGGCATCAGGTGG	26	85

285039	5	3576	TGACAATGGGCCCGGCATCA	54	86

285040	5	3634	AGCATCACATCCAGGACGAT	54	87

285041	5	3641	CATGTCCAGCATCACATCCA	37	88

285042	5	3718	GTCTGGATCATGTTGACCCG	38	130

285043	5	3778	GTCTCCCCACACAGGCAGGC	72	89

285044	5	3783	TGGTGGTCTCCCCACACAGG	28	90

285045	5	3788	AGGGATGGTGGTCTCCCCAC	27	91

285046	5	4057	CGTGTGTAGCTGTCAGTCAG	42	92

285047	5	4084	TGCAGGGTCACGATGAAGGC	28	93

285048	5	4127	GTAGACCAGCCGCCAGAAGT	28	94

285049	5	4186	CAGGCGGAGTTGGACTGGTT	55	95

285050	5	4432	TGCCACTTGTCCACCTCAGC	74	96

285051	5	4570	GTTTTGGCAGCAAAGAAAAC	44	97

285052	5	4677	GCGCCTGCTATCTCAACTCC	67	131

285053	5	4800	CAGTGTCCGTCCGTTCCAGT	44	132

285054	5	5621	ATCTACAGTTTACAGATGGG	48	102

285055	5	5626	GTCATATCTACAGTTTACAG	45	103

285056	5	5631	CAGTAGTCATATCTACAGTT	44	104

285057	5	5636	TAGGTCAGTAGTCATATCTA	36	105

285058	5	5713	TGGCATTCAGAGAGCACATT	33	133

EXAMPLE 5 Antisense Inhibition of PTPRU by Chimeric Phosphorothioate Oligonucleotides having 2′-MOE Wings and a Deoxy Gap: Dose Response Studies

In a further embodiment of the present invention, oligonucleotides were selected for dose-response studies. A549 cells were treated with 10, 20, 40, or 80 nM of PTPRU antisense oligonucleotides Compound # 285001, Compound # 285008, Compound # 285056 or Compound # 356189. Control oligonucleotide Compound # 141923 also was included in this study. Target mRNA levels were measured as described in other examples herein. Untreated cells served as the control to which the data were normalized.

Results of these studies are shown in Table 6. Data are averages from three experiments and are expressed as percent inhibition relative to untreated control.

TABLE 6

Inhibition of PTPRU mRNA expression in A549 Cells

	% Inhibition
	Dose of oligonucleotide

Compound #	SEQ ID NO	10 nM	20 nM	40 nM	80 nM

285001	55	46	64	78	81
285008	62	38	56	62	70
285056	104	36	60	71	74
356189	106	38	52	61	57
141923	138	4	5	0	0

A second screen was performed to test dose response with additional PTPRU oligonucleotides. A549 cells were treated with 10, 20, 40, or 80 nM of PTPRU antisense oligonucleotides Compound # 284986, Compound # 284995, Compound # 284998 and Compound # 285000. Control oligonucleotides Compound # 129700 and Compound # 141923 also were included in this study. Target mRNA levels were measured as described in other examples herein. Untreated cells served as the control to which the data were normalized.

Results of these studies are shown in Table 7. Data are averages from three experiments and are expressed as percent inhibition relative to untreated control.

TABLE 7

Inhibition of PTPRU mRNA expression in A549 Cells

	% Inhibition
	Dose of oligonucleotide

Compound #	SEQ ID NO	10 nM	20 nM	40 nM	80 nM

284986	40	31	54	66	71
284995	49	46	55	69	82
284998	52	30	56	72	81
285000	54	33	48	61	51
141923	138	0	0	0	0
129700	139	0	0	0	0

As shown in Table 6 and Table 7, each of the PTPRU antisense oligonucleotides tested were effective at reducing PTPRU mRNA levels in a dose-dependent manner.

EXAMPLE 6 Antisense Inhibition of Mouse PTPRU Expression by Antisense Compounds: A Second Screen of Antisense Compounds in RAW Cells

In accordance with the present invention, a second series of antisense compounds was designed to target regions of mouse PTPRU, using published sequences cited in Table 1. The compounds are shown in Table 8. All compounds in Table 8 are chimeric oligonucleotides (“gapmers”) 20 nucleotides in length, composed of a central “gap” region consisting of 10 2′-deoxynucleotides, which is flanked on both sides (5′ and 3′) by five-nucleotide “wings”. The wings are composed of 2′-O-(2-methoxyethyl) nucleotides, also known as 2′-MOE nucleotides. The internucleoside (backbone) linkages are phosphorothioate throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on gene target mRNA levels by quantitative real-time PCR as described in other examples herein, using the following primer-probe set designed to hybridize to mouse PTPRU:

	Forward primer: GGCACAGCAAACGAGGATTT

	(incorporated herein as SEQ ID NO: 256)

	Reverse primer: GCAGACCAACGCAGAAACTG

	(incorporated herein as SEQ ID NO: 257)

And the PCR probe was:
FAM-TCCCGAGTGTTCCGGGT-MGB (incorporated herein as SEQ ID NO: 258), where FAM is the fluorescent dye and MGB is the quencher dye. Data are averages from three experiments in which RAW 264.7 cells were treated with 100 nM of the disclosed antisense compounds using LIPOFECTIN™. A reduction in expression is expressed as percent inhibition in Table 8.

TABLE 8

Inhibition of mouse PTPRU miRNA levels in RAW cells
by chimeric oligonucleotides having 2′-MOE wings and
deoxy gap

284988	5	678	ACAGGAAGTAGCTGAACTGC	4	42

284992	5	797	AGCCTGGTGCCACTGACGGC	23	46

284998	5	1288	GAGTTGGTGTTGAGCTGGAT	19	52

285015	5	2332	GCCAGGGCCGTCTCAAAGGT	35	122

348312	5	29	TAAAGTTGCAGGAGCCAGAT	19	140

348314	5	136	ACAATGAACACGTAAGTGCC	3	141

348315	5	258	GCGGAGCGGGACTGGCGCCG	0	142

348316	5	300	CGGGAGCCCAAGGCGAGCGG	26	143

348317	5	351	CCTAGGTCCTGGAGACCCGC	8	144

348320	5	527	GATCCGCACTTGCTCCCATT	50	145

348321	5	620	GATGTGGGCCCTCTGACCTG	12	146

348324	5	674	GAAGTAGCTGAACTGCACAC	0	147

348325	5	676	AGGAAGTAGCTGAACTGCAC	0	148

348326	5	680	GTACAGGAAGTAGCTGAACT	28	149

348328	5	684	TGCTGTACAGGAAGTAGCTG	0	150

348329	5	791	GTGCCACTGACGGCCGTGGG	0	151

348330	5	793	TGGTGCCACTGACGGCCGTG	0	152

348331	5	795	CCTGGTGCCACTGACGGCCG	0	i53

348332	5	799	TCAGCCTGGTGCCACTGACG	16	i54

348334	5	803	CAGCTCAGCCTGGTGCCACT	15	155

348336	5	814	GTGCTGACAGCCAGCTCAGC	0	156

348340	5	848	CTCAAACAGCACCTGAAACT	20	157

348342	5	854	GAGGGCCTCAAACAGCACCT	48	158

348343	5	856	ATGAGGGCCTCAAACAGCAC	26	159

348344	5	858	AGATGAGGGCCTCAAACAGC	0	160

348345	5	886	AAGCCTATGTAGCCCTTGTG	60	161

348346	5	911	ATAGCTGAAGAGCAAGATGT	11	162

348347	5	959	GACCTCCACGTCCCCAAGGC	0	i63

348348	5	989	GCATTGGAAGGATGCGTTCT	47	164

348349	5	1025	GAAGTGTTCTGCCTCTGCGG	2	i65

348350	5	1055	CACCAGCACTCCACTCTGAC	1	166

348351	5	1084	TGACTGATGTGCCGCACCCC	0	167

348352	5	1105	AAAGTGGCCAGGAAGCGACG	0	i68

348353	5	1137	CCTGCTCTGAGCGGCCTACC	0	169

348354	5	1186	TTGGAGACGCCAGCACCACG	7	170

348355	5	1221	GGGTGGGAGGCTCTTTGACG	0	171

348356	5	1282	GTGTTGAGCTGGATAATGAG	0	172

348357	5	1284	TGGTGTTGAGCTGGATAATG	0	173

348359	5	1290	TGGAGTTGGTGTTGAGCTGG	3	174

348360	5	1292	GATGGAGTTGGTGTTGAGCT	28	175

348361	5	1294	ATGATGGAGTTGGTGTTGAG	3	176

348362	5	1400	CAGATGCCACAGCTTGTAGG	30	177

348363	5	1432	AGCACGCTGATTTCATACTC	0	178

348364	5	1459	GTGCCTCCATCTCCCGGGCG	11	179

348366	5	1538	AGCAAAAGCCAGACCTTTGG	0	180

348367	5	1930	TAGCTGATCTCATACTGAGT	39	181

348369	5	1987	ATGGTGCGTCTCGGGCCGGG	0	182

348370	5	2018	GACGTGGTAAGTCTCATTCC	0	183

348371	5	2046	ACGTGGTGCCGGGATGCAGG	30	184

348373	5	2108	TATCTCAGTGAGAGCCGCCT	9	185

348374	5	2135	AAAGCTGGGAGCTGAGATGT	0	186

348375	5	2147	GTCGGCATAATCAAAGCTGG	0	187

348376	5	2149	ATGTCGGCATAATCAAAGCT	38	188

348377	5	2151	GCATGTCGGCATAATCAAAG	33	189

348378	5	2155	GACGGCATGTCGGCATAATC	6	190

348380	5	2159	GGGTGACGGCATGTCGGCAT	39	191

348381	5	2322	TCTCAAAGGTCAGAGGTACC	22	192

348383	5	2326	GCCGTCTCAAAGGTCAGAGG	28	193

348386	5	2334	GAGCCAGGGCCGTCTCAAAG	5	194

348388	5	2338	CCGCGAGCCAGGGCCGTCTC	12	195

348389	5	2340	GGCCGCGAGCCAGGGCCGTC	0	196

348390	5	2342	CAGGCCGCGAGCCAGGGCCG	6	197

348391	5	2365	AGTTCAGCCCCAAAGTAGTG	0	198

348392	5	2393	CATGGCCTCAAGCAGGCTGC	0	199

348393	5	2421	AGGTCTGGTTGTCACCCACG	0	200

348395	5	2478	GGAAATAGATGAGATAGGCC	0	201

348396	5	2504	TTCCCCTTTCAGGTGGCTTG	0	202

348397	5	2532	TGGCAATTCGGATGCAGTTC	0	203

348398	5	2558	CTTGCTCTCCTTGCACGCAG	21	204

348399	5	2601	TGAGCCCCATCTCCTCCGAT	41	205

348400	5	2629	GCAAGACCACCTGCACAGAT	42	206

348401	5	2656	ATGGCCCCCAGGAGGAGAAT	19	207

348402	5	2686	ACTGGCTTCCCTTTGCGGAT	53	208

348403	5	2715	GGTAGTTGACCGTGGGTTTC	0	209

348404	5	2743	GCACTCATCATGTGAGTCTT	18	210

348405	5	2773	GTACTCTGATCTGTGAAGCT	27	211

348406	5	2803	GACAGACCCAACCGCTCATC	16	212

348408	5	2862	CGGTGACACCACCGCTTCGC	30	213

348409	5	2892	TTGGAGAACCCCCCAGGAGG	50	214

348410	5	2924	ATACGGAGAACCCTTCCGGC	0	215

348411	5	3779	GGTCTCCCCACACAGGCAGG	39	216

348412	5	3799	AACTCGTTGACAGGGATGGT	1	217

348413	5	3824	GATCATCTCCGTGTAGGTGG	23	218

348415	5	3873	TCTGGAACTCTTCCCGAAGC	16	219

348417	5	3929	CAGCAGGGCAATGCTACACT	5	220

348419	5	4036	GCTGCATTGATGTAGTTATT	0	221

348420	5	4211	CTCCGGCCAGTACTGCAAGC	0	222

348421	5	4238	CATGAGCCCATACTGCTGTC	0	223

348422	5	4266	TTGCTGTGCCAGACACAAAC	0	224

348424	5	4321	TCCTGCAGCCGAGAAGAGTT	75	225

348426	5	4379	CGTGTCCCGATAAGCAGACC	15	226

348427	5	4406	GTGCAGAAAGGCCTTCCTGG	55	227

348428	5	4900	TCTGCACAGGTCTGCAGGGC	6	228

348429	5	4928	ACTAGCTATTTTGGTCCAGG	0	229

348430	5	4976	GGCCAAGGACTGTGATGGAG	4	230

348431	5	5006	GGTGCTCTCTGCAGACACTC	19	231

348432	5	5036	CAGAAAGGACCATACTGGGT	35	232

348433	5	5067	CTGCCAAGTCCCAGTGAGCC	20	233

348435	5	5188	GCAAAGCACCCCAGGTCTGT	30	234

348436	5	5220	GCAGGAAAAGCTCAGAAGCA	0	235

348437	5	5255	GGGATGGAGCCCAGGAAGGA	13	236

348438	5	5293	AGCTGAAGTATATCATTCTG	18	237

348439	5	5344	CCAAGCTGAGCAGGACTGAA	0	238

348440	5	5367	CAGCCTTGTGGATTGTCACA	31	239

348441	5	5377	GGCTGTGATTCAGCCTTGTG	0	240

348442	5	5414	CAGCCTCACCAAGAGCCACA	0	241

348443	5	5428	CCCCGATCCAGTGGCAGCCT	32	242

348444	5	5449	CACCAGCCCTGTTCTAGCCT	29	243

348445	5	5464	TACTCTAGGAGCTGACACCA	0	244

348446	5	5482	GTATCCCTTCTTCCTCTGTA	0	245

348447	5	5497	GTCCTCCATTCCAAAGTATC	27	246

348448	5	5511	CAAAAAAAGCACTGGTCCTC	27	247

348449	5	5530	AATAACAAAATAACAACAAC	3	248

348450	5	5539	CATCAAAAAAATAACAAAAT	10	249

348451	5	5559	AAGAGAACTTCCCACCCTCC	24	250

348452	5	5564	TTATAAAGAGAACTTCCCAC	5	251

348453	5	5625	TCATATCTACAGTTTACAGA	0	252

348454	5	5652	ACAGCCCCCTGTGAGGTAGG	17	253

348455	5	5677	TACAAACATTACCTTACACC	0	254

348456	5	5707	TCAGAGAGCACATTTATTTA	0	255

In a further embodiment of the present invention, seven PTPRU oligonucleotides were selected for dose-response studies. RAW cells were treated with 5, 10, 25, 50, 100 or 200 nM of PTPRU antisense oligonucleotides Compound # 348343, Compound # 348345, Compound # 349348, Compound # 348400, Compound # 348424, Compound # 343427 or Compound # 284996. Control oligonucleotide Compound # 141923 also was included in this study. Target mRNA levels were measured as described in other examples herein. Untreated cells served as the control to which the data were normalized.

Results of these studies are shown in Table 9. Data are averages from three experiments and are expressed as percent inhibition relative to untreated control for the oligonucleotide doses shown below.

TABLE 9

% Inhibition of PTPRU mRNA expression in RAW Cells

Compound	SEQ ID		10
#	NO	5 nM	nM	25 nM	50 nM	100 nM	200 nM

348343	159	42	23	23	50	72	70
348345	161	28	36	1	39	48	68
348348	164	0	0	0	19	30	51
348400	206	0	0	23	45	59	73
348424	225	8	31	9	30	46	54
348427	227	0	16	7	0	30	64
284996	50	0	0	24	50	65	70
141923	138	31	44	47	10	17	3

As shown in Table 9, each of the PTPRU antisense oligonucleotides tested demonstrated a dose-responsive effect on PTPRU mRNA inhibition at doses of 10 or 25 nM and greater.

In a further embodiment of the present invention, four PTPRU oligonucleotides were selected for in vivo studies in lean mice. Six-week old male C57BL/6J-Lepr ob/ob+/−mice (Jackson Laboratory, Bar Harbor, Me.) were subcutaneously injected with PTPRU antisense oligonucleotide Compound # 284996, Compound # 349345, Compound # 348424 or Compound # 348427 at a dose of 50 mg/kg two times per week for two weeks (four total doses). Saline-injected animals served as controls. Each treatment group was comprised of five animals. After the treatment period, mice were sacrificed and target levels were evaluated in liver. RNA isolation and target mRNA expression level quantitation were performed using RIBOGREEN™ as described by other examples herein. Results are shown in Table 10 as percent inhibition of PTPRU mRNA as compared to saline treated control.

TABLE 10

Inhibition of PTPRU expression in liver of lean mice treated with
PTPRU antisense oligonucleotide

Treatment	SEQ ID NO	% Inhibition

Compound # 284996	50	63
Compound # 348345	161	77
Compound # 348424	225	82
Compound # 348427	227	64

These results demonstrate that PTPRU antisense oligonucleotides effectively reduce PTPRU expression in cell culture and in vivo.

EXAMPLE 7 Impaired Insulin Receptor Signaling in ob/ob and db/db Mice

Leptin is a hormone produced by fat that regulates appetite. Deficiencies in this hormone in both humans and non-human animals leads to obesity. ob/ob mice have a mutation in the leptin gene and db/db mice have a mutation in the leptin receptor gene. Both mutations result in obesity and hyperglycemia. As such, both types of mice are a useful model for the investigation of obesity and diabetes and treatments designed to treat these conditions. db/db mice, which have lower circulating levels of insulin and are more hyperglycemic than ob/ob mice, are often used as a rodent model of type 2 diabetes.

To characterize insulin receptor signaling in ob/ob and db/db mice, the activation states of selected proteins within the insulin receptor pathway were determined following insulin administration. Three of the key players in the insulin receptor signaling pathway are the insulin receptor .beta. subunit (IR-.beta.), PI3-Kinase and Akt. When activated, PI3-Kinase converts 4,5-PIP.sub.2 to 3,4,5-PIP.sub.3 and IR-.beta. and Akt are tyrosine phosphorylated.

Control, C57BL/6J-Lepr ob/ob mice (Jackson Laboratory, Bar Harbor, Me.) or C57B1/6J-Lepr db/db mice (Jackson Laboratory, Bar Harbor, Me.) were injected with 2 U/kg of insulin. After 2, 5, and 30 minutes, animals were sacrificed and liver samples were harvested and processed for PI3-Kinase activity and western blot analysis according to standard procedures. Briefly, to detect PI3-Kinase activity, liver samples were homogenized and immunoprecipitated with anti-IRS-1 antibody (1.5 .micro.g/mg protein) (Upstate Cell Signaling Solutions, Charlottesville, Va.). After washing the immunecomplex pellet, the sample was incubated at 30 .deg.C for 15-30 minutes with .gamma.-.sup.32P-ATP and phosphatidyl inositol substrate. Lipid was then extracted and phosphorylated lipid (PIP.sub.) was resolved by thin-layer chromatography. Plates were exposed to film and the signal was quantitated. To detect phospho-IR-.beta., liver homogenates were immunoprecipitated with anti-phosphotyrosine antibody (4G10, 1.5 .micro.g/mg protein; Upstate Cell Signaling Solutions) and immunoprecipitated protein was subjected to western blotting using anti-IR-.beta. antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.). To detect phosphorylated Akt, lysates were subjected to western blot using anti-p-Akt.sup.473antibody (Cell Signaling Technology, Beverly, Mass.).

In normal control mice, PI3-Kinase activity was detected as early as 2 minutes following insulin injection, but was greatest at 15 minutes. In both ob/ob and db/db mice, little to no PI3-Kinase activity was detected in response to insulin. Similarly, western blot analysis demonstrated that IR-.beta. and Akt phosphorylation increases in response to insulin in control mice, with a peak around 15 minutes after injection. In contrast, ob/ob and db/db mice exhibit little to IR-.beta. and Akt phosphorylation in response to insulin administration. Thus, these results demonstrate that ob/ob and db/db mice have deficiencies in insulin receptor signaling.

EXAMPLE 8 Effects of Antisense Inhibition of PTPRU: In Vivo Study in ob/ob Mice

In accordance with the present invention, the antisense compounds of the invention were tested in the ob/ob model of obesity and diabetes.

Six-week old male C57BL/6J-Lepr ob/ob mice (Jackson Laboratory, Bar Harbor, Me.) were subcutaneously injected with PTPRU antisense oligonucleotide Compound # 284996 (SEQ ID NO: 50) at a dose of 25 mg/kg two times per week for 4 weeks (eight total doses). Saline-injected animals served as controls. Each treatment group was comprised of six animals. After the treatment period, mice were sacrificed and target levels were evaluated in liver. RNA isolation and target mRNA expression level quantitation were performed using RIBOGREEN™ as described by other examples herein. As compared to saline-treated control animals, treatment with Compound # 284996 resulted in a 60% reduction in PTPRU expression.

The effects of target inhibition on glucose metabolism were evaluated in ob/ob mice treated with PTPRU antisense oligonucleotide Compound # 284996. Plasma glucose was measured prior 3 days prior to the start of treatment and at 12, 19 and 26 days following the first dose. Glucose levels were measured by routine clinical methods using a YSI glucose analyzer (YSI Scientific, Yellow Springs, Ohio). Average plasma glucose levels (in mg/dL) for each treatment group are shown in Table 11.

TABLE 11

Effect of PTPRU antisense oligonucleotide on plasma glucose
levels in ob/ob mice

		Day 12	Day 19	Day 26
Treatment	Day −3 (mg/dL)	(mg/dL)	(mg/dL)	(mg/dL)

Saline	375	420	432	427
Compound #	374	425	375	303
284996

As shown in Table 11, treatment with PTPRU antisense oligonucleotide significantly reduces plasma glucose levels of ob/ob mice.

To assess the effects of inhibition of target mRNA on triglyceride levels, the ob/ob mice were further evaluated 3 days prior to the start of treatment and at 12, 19 and 26 days following the first dose of oligonucleotide for plasma triglycerides (TRIG). Triglycerides were measured by routine clinical analyzer instruments (e.g. Olympus Clinical Analyzer, Melville, N.Y.). Average levels of TRIG (mg/dL) measured for each treatment group are shown in Table 12.

TABLE 12

Triglyceride levels of ob/ob mice treated with PTPRU antisense
oligonucleotide

Treatment	Day −3	Day 12	Day 19	Day 26

Saline	145	192	152	125
Compound #	125	140	114	117
284996

As shown in Table 12, treatment with PTPRU antisense oligonucleotide resulted in a reduction in plasma triglyceride levels.

Antisense oligonucleotide-treated and saline control ob/ob mice were further evaluated for PI3-Kinase activity and IR-.beta. phosphorylation following insulin administration as described in other examples herein. As expected, in saline control ob/ob mice, PI3-Kinase activation and IR-.beta. phosphorylation were not observed in response to insulin treatment. In contrast, treatment with antisense oligonucleotide to PTPRU resulted in greater activation of PI3-Kinase and IR-.beta. phosphorylation relative to mice that did not receive insulin. Taken together, these results demonstrate that PTPRU antisense oligonucleotide treatment lowers plasma glucose and triglyceride levels of ob/ob mice and increases insulin responsiveness in these animals.

EXAMPLE 9 Effects of Antisense Inhibition of PTPRU: A Second In Vivo Study in ob/ob Mice

In accordance with the present invention, a second study of PTPRU antisense inhibition was performed in ob/ob mice. Six-week old male C57BL/6J-Lepr ob/ob mice (Jackson Laboratory, Bar Harbor, Me.) were subcutaneously injected with PTPRU antisense oligonucleotide Compound # 284996 (SEQ ID NO: 50) or Compound # 285015 (SEQ ID NO: 122) at a dose of 25 mg/kg two times per week for 4 weeks (eight total doses). Saline-injected animals served as controls. Each treatment group was comprised of six animals. After the treatment period, mice were sacrificed and target levels were evaluated in liver. RNA isolation and target mRNA expression level quantitation were performed using RIBOGREEN™ as described by other examples herein. As compared to saline-treated control animals, treatment with Compound # 284996 and Compound # 285015 resulted in a 53% and 34% reduction, respectively, in PTPRU expression.

The effects of target inhibition on glucose metabolism were evaluated in ob/ob mice treated with PTPRU antisense oligonucleotides Compound # 284996 and Compound # 285015. Plasma glucose was measured prior to the start of treatment (Week 0) and at Week 2 and Week 4. Glucose levels were measured by routine clinical methods using a YSI glucose analyzer (YSI Scientific, Yellow Springs, Ohio). Average plasma glucose levels (in mg/dL) for each treatment group are shown in Table 13.

TABLE 13

Effect of PTPRU antisense oligonucleotide on plasma glucose
levels in ob/ob mice

	Week 0	Week 2	Week 4
Treatment	(mg/dL)	(mg/dL)	(mg/dL)

Saline	375	450	430
Compound #	359	306	239
284996
Compound #	359	314	243
285015

As shown in Table 13, treatment with PTPRU antisense oligonucleotide significantly reduces plasma glucose levels of ob/ob mice.

To assess triglyceride levels after inhibition of target mRNA, the ob/ob mice were further evaluated at the termination of treatment for plasma triglycerides (TRIG). Triglycerides were measured by routine clinical analyzer instruments (e.g. Olympus Clinical Analyzer, Melville, N.Y.). Average levels of TRIG (mg/dL) measured for each treatment group are shown in Table 14.

TABLE 14

Effects of PTPRU antisense oligonucleotide treatment on triglyceride
levels in ob/ob mice

		TRIG
	Treatment	(mg/dL)

	Saline	218
	Compound #	110
	284996
	Compound #	93
	285015

Taken together, the results of these studies demonstrate that PTPRU antisense oligonucleotides reduce target mRNA levels in vivo and lead to a reduction in plasma glucose and triglyceride levels in ob/ob mice.

EXAMPLE 10 Effects of Antisense Inhibition of PTPRU: In Vivo Study in db/db Mice

In accordance with the present invention, the antisense compounds of the invention were tested in the db/db model of obesity and diabetes. Six-week old male C57BL/6J-Lepr db/db mice (Jackson Laboratory, Bar Harbor, Me.) were subcutaneously injected with PTPRU antisense oligonucleotide Compound # 284996 (SEQ ID NO: 50) or Compound # 285015 (SEQ ID NO: 122) at a dose of 25 mg/kg two times per week for 4 weeks (eight total doses). Saline-injected animals served as controls. Each treatment group was comprised of six animals. After the treatment period, mice were sacrificed and target levels were evaluated in liver. RNA isolation and target mRNA expression level quantitation were performed using RIBOGREEN™ as described by other examples herein. As compared to saline-treated control animals, treatment with Compound # 284996 and Compound # 285015 resulted in a 45% and 31% reduction, respectively, in PTPRU expression.

The effects of target inhibition on glucose metabolism were evaluated in db/db mice treated with PTPRU antisense oligonucleotides Compound # 284996 and Compound # 285015. Plasma glucose was measured prior to the start of treatment (Week 0) and at Week 2 and Week 4. Glucose levels were measured by routine clinical methods using a YSI glucose analyzer (YSI Scientific, Yellow Springs, Ohio). Average plasma glucose levels (in mg/dL) for each treatment group are shown in Table 15.

TABLE 15

Effect of PTPRU antisense oligonucleotide on plasma glucose
levels in db/db mice

	Week 0	Week 2	Week 4
Treatment	(mg/dL)	(mg/dL)	(mg/dL)

Saline	382	479	545
Compound #	383	395	464
284996
Compound #	380	411	442
285015

As shown in Table 15, treatment with PTPRU antisense oligonucleotide significantly reduces plasma glucose levels of db/db mice.

To assess triglyceride levels after inhibition of target mRNA, the db/db mice were further evaluated at the termination of treatment for plasma triglycerides (TRIG). Triglycerides were measured by routine clinical analyzer instruments (e.g. Olympus Clinical Analyzer, Melville, N.Y.). Average levels of TRIG (mg/dL) measured for each treatment group are shown in Table 16.

TABLE 16

Effects of PTPRU antisense oligonucleotide treatment on triglyceride
levels in db/db mice

		TRIG
	Treatment	(mg/dL)

	Saline	311
	Compound #	200
	284996
	Compound #	295
	285015

Taken together, the results of these studies demonstrate that PTPRU antisense oligonucleotides reduce target mRNA levels in vivo and lead to a reduction in plasma glucose and triglyceride levels in diabetic animals.

Various modifications of the disclosed compositions and methods will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. The appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention. Each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification are herein incorporated by reference in their entirety.

Claims

1. A method of reducing PTPRU comprising:

identifying an animal having an increased glucose level or an increased lipid level; and

administering to said animal a compound comprising a modified oligonucleotide consisting of 13 to 80 linked nucleosides, wherein said modified oligonucleotide has a nucleobase sequence that is at least 90% complementary to a nucleic acid sequence encoding PTPRU as measured over the entirety of said modified oligonucleotide, wherein said nucleic acid sequence encoding PTPRU is selected from the group consisting of SEQ ID NOs:1, 2, and 4, and wherein expression of said nucleic acid sequence encoding PTPRU is reduced.

2. The method of claim 1, wherein said compound consists of a single-stranded modified oligonucleotide.

3. The method of claim 2, wherein said modified oligonucleotide consists of 13 to 30 linked nucleosides.

4. The method of claim 2, wherein said nucleobase sequence of said modified oligonucleotide is 100% complementary to said nucleic acid sequence encoding PTPRU as measured over the entirety of said modified oligonucleotide.

5. The method of claim 2, wherein at least one internucleoside linkage of said modified oligonucleotide is a modified internucleoside linkage.

6. The method of claim 5, wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate internucleoside linkage.

7. The method of claim 2, wherein at least one nucleoside of said modified oligonucleotide comprises a modified sugar.

8. The method of claim 7, wherein at least one modified sugar is a bicyclic sugar.

9. The method of claim 7, wherein at least one modified sugar comprises a 2′-O-methoxyethyl.

10. The method of claim 7, wherein at least one modified sugar comprises a 4′-(CH₂)_n—O-2′ bridge, wherein n is 1 or 2.

11. The method of claim 2, wherein at least one nucleoside of said modified oligonucleotide comprises a modified nucleobase.

12. The method of claim 11, wherein the modified nucleobase is a 5-methylcytosine.

13. The method of claim 1, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5′ wing segment consisting of linked nucleosides;

a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

14. The method of claim 13, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5′ wing segment consisting of five linked nucleosides;

a 3′ wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar; and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage.

15. The method of claim 14, wherein the modified oligonucleotide consists of 20 linked nucleosides.

16. The method of claim 2, wherein the modified oligonucleotide consists of 20 linked nucleosides.

17. The method of claim 1, wherein said compound or a salt thereof is administered in a composition comprising said compound or a salt thereof and a pharmaceutically acceptable carrier or diluent.

18. The method of claim 17, wherein said compound or salt thereof consists of a single-stranded oligonucleotide.

19. The method of claim 1, wherein said animal is human and said nucleic acid sequence encoding PTPRU is SEQ ID NO:1.

20. The method of claim 1, wherein a blood glucose level of said animal is lowered.

21. The method of claim 1, wherein said animal suffers from a disease or condition associated with an increased glucose level.

22. The method of claim 21, wherein said increased glucose level is plasma glucose level.

23. The method of claim 21, wherein the disease or condition is selected from the group consisting of diabetes, type II diabetes, metabolic syndrome, insulin resistance, insulin deficiency, hyperglycemia, obesity and a combination thereof.

24. The method of claim 21, wherein the animal has a deficiency in insulin receptor signaling.

25. The method of claim 21, wherein blood glucose level of said animal is decreased, and said disease or condition is treated.

26. The method of claim 25, wherein said animal is a human.

27. The method of claim 1, wherein a lipid level of said animal is reduced.

28. The method of claim 27, wherein said lipid level is plasma triglyceride level, plasma cholesterol level, hepatic triglyceride level or a combination thereof.

29. The method of claim 1, wherein said animal is suffering from a disease or condition associated with an increased lipid level.

30. The method of claim 29, wherein the increased lipid level is plasma triglyceride level.

31. The method of claim 29, wherein the increased lipid level is hepatic triglyceride level.

32. The method of claim 29, wherein the increased lipid level is plasma cholesterol level.

33. The method of claim 29, wherein the disease or condition is selected from the group consisting of hyperlipidemia, hypertriglyceridemia, obesity, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease, coronary heart disease and a combination thereof.

34. The method of claim 29, wherein said lipid level of said animal is decreased, and said disease or condition is treated.

35. The method of claim 34, wherein said animal is a human.

36. A method of reducing PTPRU comprising:

identifying a human having an elevated lipid level; and

administering to said human a compound comprising a modified oligonucleotide consisting of 13 to 80 linked nucleosides, wherein said modified oligonucleotide has a nucleobase sequence that is at least 90% complementary to a nucleic acid sequence encoding PTPRU having SEQ ID NO:1, as measured over the entirety of said modified oligonucleotide, wherein expression of said nucleic acid sequence encoding PTPRU is reduced, and wherein said lipid level of said human is reduced.